U.S. patent application number 15/049739 was filed with the patent office on 2016-08-25 for carbamate/urea derivatives.
This patent application is currently assigned to NOVARTIS AG. The applicant listed for this patent is Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG. Invention is credited to Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG.
Application Number | 20160244426 15/049739 |
Document ID | / |
Family ID | 49263333 |
Filed Date | 2016-08-25 |
United States Patent
Application |
20160244426 |
Kind Code |
A1 |
AUBERSON; Yves ; et
al. |
August 25, 2016 |
CARBAMATE/UREA DERIVATIVES
Abstract
The invention relates to compound of the formula I ##STR00001##
or a salt thereof, wherein the substituents are as defined in the
specification; to its preparation, to its use as medicament and to
medicaments comprising it.
Inventors: |
AUBERSON; Yves; (Allscwil,
CH) ; BOCK; Mark Gary; (Boston, MA) ; BRAGA;
Dario; (Casalecchio Di Reno (Bologna), IT) ; CURZI;
Marco; (Bologna, IT) ; DODD; Stephanie Kay;
(Ayer, MA) ; GIAFFREDA; Stefano Luca; (Bologna,
IT) ; JIANG; Hayang; (Shanghai, CN) ;
KARPINSKI; Piotr; (Lincoln Park, MA) ; TROXLER;
Thomas J.; (Wahlen b. Laufen, CH) ; WANG;
Tie-Lin; (Shanghai, CN) ; WANG; Xiaoyang;
(Shanghai, CN) ; ZHANG; Xuechun; (Guilford,
CN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AUBERSON; Yves
BOCK; Mark Gary
BRAGA; Dario
CURZI; Marco
DODD; Stephanie Kay
GIAFFREDA; Stefano Luca
JIANG; Hayang
KARPINSKI; Piotr
TROXLER; Thomas J.
WANG; Tie-Lin
WANG; Xiaoyang
ZHANG; Xuechun |
Allscwil
Boston
Casalecchio Di Reno (Bologna)
Bologna
Ayer
Bologna
Shanghai
Lincoln Park
Wahlen b. Laufen
Shanghai
Shanghai
Guilford |
MA
MA
MA |
CH
US
IT
IT
US
IT
CN
US
CH
CN
CN
CN |
|
|
Assignee: |
NOVARTIS AG
Basel
CH
|
Family ID: |
49263333 |
Appl. No.: |
15/049739 |
Filed: |
February 22, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14685926 |
Apr 14, 2015 |
9273026 |
|
|
15049739 |
|
|
|
|
13944354 |
Jul 17, 2013 |
9034874 |
|
|
14685926 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07C 57/15 20130101;
C07C 59/265 20130101; A61K 31/496 20130101; A61P 25/00 20180101;
A61P 37/04 20180101; C07B 2200/13 20130101; A61P 43/00 20180101;
C07D 401/04 20130101; A61K 31/501 20130101; C07D 403/04
20130101 |
International
Class: |
C07D 401/04 20060101
C07D401/04; A61K 31/496 20060101 A61K031/496; A61K 31/501 20060101
A61K031/501 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 20, 2012 |
CN |
PCT/CN2012/078933 |
Jun 28, 2013 |
CN |
PCT/CN2013/078309 |
Claims
1. A compound of the formula I ##STR00053## or a salt thereof,
wherein R.sub.1 is C.sub.1-6alkyl, C.sub.2-6alkenyl,
C.sub.2-6alkinyl, C.sub.3-6cycloalkyl, C.sub.5-6cycloalkenyl or
C.sub.3-6cycloalkyl-C.sub.1-4alkyl; wherein said C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkinyl or
C.sub.3-6cycloalkyl-C.sub.1-4alkyl may be substituted once or more
than once by halogen; and wherein said C.sub.3-6cycloalkyl or
C.sub.5-6cycloalkenyl may be substituted once or more than once by
halogen, C.sub.1-4alkyl or C.sub.1-4halogenalkyl; m is 1 or 2; n is
0, 1, 2, 3 or 4; each R.sub.2 independently is halogen, hydroxyl,
amino, cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen; or two R.sub.2 at the same carbon atom form together
with said carbon atom a C.sub.3-6cycloalkyl; X.sub.1 is oxygen or
--N(R.sub.4)--; R.sub.4 is hydrogen, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl, or C.sub.3-6cycloalkyl-C.sub.1-2alkyl; p is 1
and q is 1; p is 0 and q is 1; or p is 0 and q is 0; r is 0, 1, 2,
3 or 4; each R.sub.3 independently is halogen, hydroxyl, amino,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen; or two R.sub.3 at the same carbon atom form together
with said carbon atom a C.sub.3-6cycloalkyl; A is ##STR00054##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; R.sub.5 is hydrogen, C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkinyl, C.sub.3-6cycloalkyl,
C.sub.5-6cycloalkenyl or C.sub.3-6cycloalkyl-C.sub.1-4alkyl;
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkinyl or
C.sub.3-6cycloalkyl-C.sub.1-4alkyl may be substituted once or more
than once by halogen, hydroxyl or C.sub.1-6alkoxy; and wherein said
C.sub.3-6cycloalkyl or C.sub.5-6cycloalkenyl may be substituted
once or more than once by halogen, C.sub.1-4alkyl or
C.sub.1-4halogenalkyl; X.sub.2 is nitrogen or carbon; s is 0, 1, 2
or 3; each R.sub.6 independently is halogen, hydroxyl, amino,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen.
2. A compound of formula I according to claim 1, wherein X.sub.1 is
oxygen; or a salt thereof.
3. A compound of formula I according to claim 1, wherein p is 1 and
q is 1; or a salt thereof.
4. A compound of formula I according to claim 1, wherein R.sub.1 is
isopropyl, cyclopropyl, cyclobutyl or cyclopentyl and m is 1; or a
salt thereof.
5. A compound of formula I according claim 1, wherein A is selected
from A3 and A4 ##STR00055## wherein the bond marked with the
asterisk is attached to the nitrogen atom; or a salt thereof.
6. A compound of formula I according to claim 1, wherein R.sub.1 is
isopropyl or cyclobutyl; m is 1; n is 0, 1 or 2; each R.sub.2
independently is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl,
C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or
two R.sub.2 at the same carbon atom form together with said carbon
atom a C.sub.3-4cycloalkyl; X.sub.1 is oxygen; p is 1 and q is 1; r
is 0, 1 or 2; wherein each R.sub.3 independently is halogen,
C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or two R.sub.3 at
the same carbon atom form together with said carbon atom a
C.sub.3-4cycloalkyl; A is selected from A3 and A4 ##STR00056##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; R.sub.5 is hydrogen or methyl; s is 0, 1 or 2; and
each R.sub.6 independently is halogen, C.sub.1-4alkyl,
C.sub.1-4halogenalkyl, C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or
C.sub.3-4cycloalkyl; or a salt thereof.
7. A compound of formula I according to claim 1, wherein said
compound is selected from the group consisting of
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate;
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate;
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate;
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclopropylpiperazine-1-carboxylate;
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate;
1-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate;
1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate;
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate;
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; and
1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; or salts of these
compounds.
8. A pharmaceutical composition comprising a therapeutically
effective amount of a compound according to claim 1 and one or more
pharmaceutically acceptable carriers.
9. A combination comprising a therapeutically effective amount of
the compound according to claim 1 and one or more therapeutically
active agents.
10. A method of treating a disorder or a disease in a subject
mediated by H3 receptors, wherein the method comprises
administering to the subject a therapeutically effective amount of
a compound according to claim 1.
11. A compound according to claim 1, for use as a medicament.
12. Use of a compound according to claim 1, for the treatment of a
disorder or disease in a subject mediated by H3 receptors.
13. Use of a compound according to claim 1, for the treatment of a
disorder or disease in a subject characterized by an abnormal
activity of H3 receptors.
14. A compound of formula II-1 ##STR00057## or a salt thereof; in
which p, q, r, R.sub.3 and A are as defined under formula I; and
R.sub.a is a leaving group.
15. A free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form; or a salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form, wherein said
salt is the citrate, hydrochloride, fumarate, adipate, maleate or
sebacate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate.
16. A pharmaceutical composition, which comprises a free form or a
salt as defined in claim 15 as active ingredient and at least one
pharmaceutically acceptable carrier.
17. A method of preparing a citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form comprising
the steps of (a) preparing a solution of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate and citric acid in acetone,
wherein the
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate:citric acid ratio is about
1:2; (b) adding to the solution of step (a) an ether antisolvent,
e.g. diethyl ether, until an acetone:ether antisolvent volume ratio
from 1:1 to 1:5 is reached; and (e) isolate the solids by
filtration to obtain the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
Description
[0001] The invention relates to carbamate/urea derivatives, to
their solid forms, to their preparation, to their use as
medicaments and to medicaments comprising them.
I. CARBAMATE/UREA DERIVATIVES
[0002] Histamine is a multifunctional chemical transmitter that
signals through specific cell surface G-protein-coupled receptors
(GPCRs). To date, four histamine receptors subtypes have been
identified: H1, H2, H3 and H4. The H3 receptor is a presynaptic
GPCR that is found predominantly in the central nervous system,
although lower levels are also found in the peripheral nervous
system. Genes encoding the H3 receptor have been reported in
various organisms, including humans, and alternative splicing of
this gene appears to result in multiple isoforms. The H3 receptor
is an auto- and heteroreceptor whose activation leads to a
decreased release of neurotransmitters (including histamine,
acetylcholine, norepinephrine, dopamine and glutamate) from neurons
in the brain, and is involved in the regulation of processes such
as sleep and wakefulness, feeding and memory. In certain systems,
the H3 receptor may be constitutively active.
[0003] Antagonists of H3 receptor increase release of cerebral
histamine and other neurotransmitters, which in turn induces an
extended wakefulness, an improvement in cognitive processes, a
reduction in food intake and a normalization of vestibular
reflexes. H3 receptor antagonists are described e.g. in Lazewska
and Kiec-Kononowicz, Expert Opin Ther Patents, 2010, 20(9),
1147-1169; Raddatz et al, Current Topics in Medicinal Chemistry,
2010, 10, 153-169; WO2007052124; WO2007016496 and WO2004101546.
[0004] As histamine pathways have been implicated in a wide range
of disorders, in particular disorders of sleep and wakefulness with
excessive daytime sleepiness, e.g. narcolepsy, H3 receptor
antagonists are considered to be useful for pharmacotherapy of said
disorders.
[0005] There is a need to provide new H3 receptor antagonists that
are good drug candidates. In particular, preferred compounds should
bind potently to H3 receptors whilst showing little affinity for
other receptors, e.g. receptors mediating significant side-effects,
such as hERG channels which may induce cardiovascular side-effects.
They should be well absorbed from the gastrointestinal tract, be
sufficiently metabolically stable, possess favorable
pharmacokinetic properties, sufficient brain uptake, fast onset and
sufficiently long duration of action. For e.g. narcolepsy
treatment, the pharmacokinetic property of the compound should lead
to good wakefulness during daytime, but should equally lead to a
minimal impact on night-sleep. The drug candidates should be
non-toxic and demonstrate few side-effects. Furthermore, the ideal
drug candidate will be able to exist in a physical form that is
stable, non-hygroscopic and easily formulated.
[0006] The compounds of the invention are H3 receptor antagonists
and are therefore potentially useful in the treatment of a wide
range of disorders, particularly narcolepsy.
[0007] In a first aspect, the invention relates to a compound of
the formula I
##STR00002##
or a salt thereof, wherein R.sub.1 is C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkinyl, C.sub.3-6cycloalkyl,
C.sub.5-6cycloalkenyl or C.sub.3-6cycloalkyl-C.sub.1-4alkyl;
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkinyl or
C.sub.3-6cycloalkyl-C.sub.1-4alkyl may be substituted once or more
than once by halogen; and wherein said C.sub.3-6cycloalkyl or
C.sub.5-6cycloalkenyl may be substituted once or more than once by
halogen, C.sub.1-4alkyl or C.sub.1-4halogenalkyl; m is 1 or 2; n is
0, 1, 2, 3 or 4; each R.sub.2 independently is halogen, hydroxyl,
amino, cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen; or two R.sub.2 at the same carbon atom form together
with said carbon atom a C.sub.3-6cycloalkyl; X.sub.1 is oxygen or
--N(R.sub.4)--; R.sub.4 is hydrogen, C.sub.1-6alkyl,
C.sub.3-6cycloalkyl, or C.sub.3-6cycloalkyl-C.sub.1-2alkyl; p is 1
and q is 1; p is 0 and q is 1; or p is 0 and q is 0; r is 0, 1, 2,
3 or 4; each R.sub.3 independently is halogen, hydroxyl, amino,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen; or two R.sub.3 at the same carbon atom form together
with said carbon atom a C.sub.3-6cycloalkyl;
A is
##STR00003##
[0008] wherein the bond marked with the asterisk is attached to the
nitrogen atom; R.sub.5 is hydrogen, C.sub.1-6alkyl,
C.sub.2-6alkenyl, C.sub.2-6alkinyl, C.sub.3-6cycloalkyl,
C.sub.5-6cycloalkenyl or C.sub.3-6cycloalkyl-C.sub.1-4alkyl;
wherein said C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkinyl or
C.sub.3-6cycloalkyl-C.sub.1-4alkyl may be substituted once or more
than once by halogen, hydroxyl or C.sub.1-6alkoxy; and wherein said
C.sub.3-6cycloalkyl or C.sub.5-6cycloalkenyl may be substituted
once or more than once by halogen, C.sub.1-4alkyl or
C.sub.1-4halogenalkyl; X.sub.2 is nitrogen or carbon; s is 0, 1, 2
or 3; each R.sub.6 independently is halogen, hydroxyl, amino,
cyano, nitro, C.sub.1-6alkyl, C.sub.1-6halogenalkyl,
C.sub.1-6hydroxyalkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl,
amino-C.sub.1-6alkyl, C.sub.1-4alkyl-amino-C.sub.1-6alkyl,
di(C.sub.1-4alkyl)-amino-C.sub.1-6alkyl, C.sub.1-6alkoxy,
C.sub.1-6halogenalkoxy, C.sub.1-6alkylamino,
di(C.sub.1-6alkyl)amino, C.sub.2-6alkenyl, C.sub.2-6halogenalkenyl,
C.sub.2-6alkinyl or C.sub.2-6halogenalkinyl; or
C.sub.3-6cycloalkyl, wherein one carbon atom may be replaced by an
oxygen atom, wherein the C.sub.3-6cycloalkyl may be attached
directly to the methylene or via a C.sub.1-2alkylene, and wherein
the C.sub.3-6cycloalkyl may be substituted once or more than once
by halogen.
[0009] Unless specified otherwise, the term "compounds of the
invention" refers to compounds of formula (I) and subformulae
thereof (e.g. compounds of formula (I-1)); prodrugs thereof; solid
forms of free forms or salts of the compounds, e.g. SOLID FORMS OF
THE INVENTION, and/or prodrugs; hydrates or solvates of the
compounds, salts and/or prodrugs; as well as all stereoisomers
(including diastereoisomers and enantiomers), tautomers and
isotopically labeled compounds (including deuterium substitutions);
as well as inherently formed moieties (e.g. polymorphs, solvates
and/or hydrates).
[0010] Unless indicated otherwise, the expressions used in this
invention have the following meaning:
[0011] "Alkyl" represents a straight-chain or branched-chain alkyl
group and, for example, may be methyl, ethyl, n- or iso-propyl, n-,
iso-, sec- or tert-butyl, n-pentyl, n-hexyl; C.sub.1-6alkyl
preferably represents a straight-chain or branched-chain
C.sub.1-4alkyl with particular preference given to methyl, ethyl,
n-propyl, iso-propyl and tert-butyl.
[0012] Each alkyl part of "alkoxy", "halogenalkyl" and so on shall
have the same meaning as described in the above-mentioned
definition of "alkyl", especially regarding linearity and
preferential size.
[0013] "C.sub.3-6cycloalkyl" represents a saturated alicyclic
moiety having from three to six carbon atoms. This term refers to
groups such as cyclopropyl, cyclobutyl, cyclopentyl and
cyclohexyl.
[0014] A substituent being substituted "once or more than once",
e.g. as defined in connection with R.sub.1, is preferably
substituted by one to three substituents.
[0015] Halogen is generally fluorine, chlorine, bromine or iodine;
preferably fluorine, chlorine or bromine. Halogenalkyl groups
preferably have a chain length of 1 to 4 carbon atoms and are, for
example, fluoromethyl, difluoromethyl, trifluoromethyl,
chloromethyl, dichloromethyl, trichloromethyl,
2,2,2-trifluoroethyl, 2-fluoroethyl, 2-chloroethyl,
pentafluoroethyl, 1,1-difluoro-2,2,2-trichloroethyl,
2,2,2-trichloroethyl, 1,1,2,2-tetrafluoroethyl,
2,2,3,3-tetrafluoropropyl, 2,2,3,3,3-pentafluoropropyl or
2,2,3,4,4,4-hexafluorobutyl.
[0016] In the event X.sub.2 being carbon, said carbon can be
unsubstituted, substituted by a R.sub.6 or used to attach A to the
nitrogen of the neighbouring piperidine/pyrrolidine/azetidine
moiety.
[0017] Compounds of formula I may exist in optically active form or
in form of mixtures of optical isomers, e.g. in form of racemic
mixtures or diastereomeric mixtures. In particular, asymmetrical
carbon atom(s) may be present in the compounds of formula I and
their salts. Unless otherwise provided herein, all optical isomers
and their mixtures, including the racemic mixtures, are embraced by
the invention.
[0018] As used herein, the term "isomers" refers to different
compounds that have the same molecular formula but differ in
arrangement and configuration of the atoms. Also as used herein,
the term "an optical isomer" or "a stereoisomer" refers to any of
the various stereo isomeric configurations which may exist for a
given compound of the invention and includes geometric isomers. It
is understood that a substituent may be attached at a chiral center
of a carbon atom. The term "chiral" refers to molecules which have
the property of non-superimposability on their mirror image
partner, while the term "achiral" refers to molecules which are
superimposable on their mirror image partner. Therefore, the
invention includes enantiomers, diastereomers or racemates of the
compound. "Enantiomers" are a pair of stereoisomers that are
non-superimposable mirror images of each other. A 1:1 mixture of a
pair of enantiomers is a "racemic" mixture. The term is used to
designate a racemic mixture where appropriate. "Diastereoisomers"
are stereoisomers that have at least two asymmetric atoms, but
which are not mirror-images of each other. The absolute
stereochemistry is specified according to the Cahn-Ingold-Prelog
R-S system. When a compound is a pure enantiomer the
stereochemistry at each chiral carbon may be specified by either R
or S. Resolved compounds whose absolute configuration is unknown
can be designated (+) or (-) depending on the direction (dextro- or
levorotatory) which they rotate plane polarized light at the
wavelength of the sodium D line. The compounds described herein may
contain one or more asymmetric centers and may thus give rise to
enantiomers, diastereomers, and other stereoisomeric forms that may
be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
Unless otherwise provided herein, the invention is meant to include
all such possible isomers, including racemic mixtures, optically
pure forms and intermediate mixtures. Optically active (R)- and
(S)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques.
[0019] If the compound contains a double bond, the substituent may
be E or Z configuration.
[0020] If the compound contains a disubstituted cycloalkyl, the
cycloalkyl substituent may have a cis- or trans-configuration.
[0021] Any asymmetric atom (e.g. carbon or the like) of the
compound(s) of the invention can be present in racemic or
enantiomerically enriched, for example the (R)-, (S)- or
(R,S)-configuration. In certain embodiments, each asymmetric atom
has at least 50 enantiomeric excess, at least 60% enantiomeric
excess, at least 70% enantiomeric excess, at least 80% enantiomeric
excess, at least 90% enantiomeric excess, at least 95 enantiomeric
excess, or at least 99% enantiomeric excess in the (R)- or
(S)-configuration. Substituents at atoms with unsaturated bonds
may, if possible, be present in cis-(Z)- or trans-(E)-form.
[0022] Accordingly, as used herein, a compound of the invention can
be in the form of one of the possible isomers, rotamers,
atropisomers, tautomers or mixtures thereof, for example, as
substantially pure geometric (cis or trans) isomers, diastereomers,
optical isomers (antipodes), racemates or mixtures thereof.
[0023] Any resulting mixtures of isomers can be separated on the
basis of the physicochemical differences of the constituents, into
the pure or substantially pure geometric or optical isomers,
diastereomers, racemates, for example, by chromatography and/or
fractional crystallization.
[0024] Any resulting racemates of final products or intermediates
can be resolved into the optical antipodes by known methods, e.g.,
by separation of the diastereomeric salts thereof, obtained with an
optically active acid or base, and liberating the optically active
acidic or basic compound. In particular, a basic moiety may thus be
employed to resolve the compounds of the invention into their
optical antipodes, e.g., by fractional crystallization of a salt
formed with an optically active acid, e.g., tartaric acid,
dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl
tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic
acid. Racemic products can also be resolved by chiral
chromatography, e.g., high pressure liquid chromatography (HPLC)
using a chiral adsorbent.
[0025] Depending on substituent definition, compounds of formula I
may occur in various tautomeric forms. All tautomeric forms of the
compounds of formula I are embraced by the invention.
[0026] As used herein, the terms "salt" or "salts" refers to an
acid addition or base addition salt of a respective compound, e.g.
a compound of the invention or of a compound of formula II-1.
"Salts" include in particular "pharmaceutically acceptable salts".
The term "pharmaceutically acceptable salts" refers to salts that
retain the biological effectiveness and properties of the compounds
of this invention and, which typically are not biologically or
otherwise undesirable. The compounds of the invention may be
capable of forming acid and/or base salts by virtue of the presence
of amino and/or carboxyl groups or groups similar thereto.
[0027] Pharmaceutically acceptable acid addition salts can be
formed with inorganic acids and organic acids, e.g., acetate,
aspartate, benzoate, besylate, bromide/hydrobromide,
bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate,
chloride/hydrochloride, chlortheophyllonate, citrate,
ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,
hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate,
laurylsulfate, malate, maleate, malonate, mandelate, mesylate,
methylsulphate, naphthoate, napsylate, nicotinate, nitrate,
octadecanoate, oleate, oxalate, palmitate, pamoate,
phosphate/hydrogen phosphate/dihydrogen phosphate,
polygalacturonate, propionate, stearate, succinate,
sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
[0028] Inorganic acids from which salts can be derived include, for
example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, and the like.
[0029] Organic acids from which salts can be derived include, for
example, acetic acid, propionic acid, glycolic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, mandelic acid, methanesulfonic
acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic
acid, and the like. Pharmaceutically acceptable base addition salts
can be formed with inorganic and organic bases.
[0030] Inorganic bases from which salts can be derived include, for
example, ammonium salts and metals from columns I to XII of the
periodic table. In certain embodiments, the salts are derived from
sodium, potassium, ammonium, calcium, magnesium, iron, silver,
zinc, and copper; particularly suitable salts include ammonium,
potassium, sodium, calcium and magnesium salts.
[0031] Organic bases from which salts can be derived include, for
example, primary, secondary, and tertiary amines, substituted
amines including naturally occurring substituted amines, cyclic
amines, basic ion exchange resins, and the like. Certain organic
amines include isopropylamine, benzathine, cholinate,
diethanolamine, diethylamine, lysine, meglumine, piperazine and
tromethamine.
[0032] The pharmaceutically acceptable salts of the invention can
be synthesized from a basic or acidic moiety, by conventional
chemical methods. Generally, such salts can be prepared by reacting
free acid forms of these compounds with a stoichiometric amount of
the appropriate base (such as Na, Ca, Mg, or K hydroxide,
carbonate, bicarbonate or the like), or by reacting free base forms
of these compounds with a stoichiometric amount of the appropriate
acid. Such reactions are typically carried out in water or in an
organic solvent, or in a mixture of the two. Generally, use of
non-aqueous media like ether, ethyl acetate, ethanol, isopropanol,
or acetonitrile is desirable, where practicable. Lists of
additional suitable salts can be found, e.g., in "Remington's
Pharmaceutical Sciences", 20th ed., Mack Publishing Company,
Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts:
Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH,
Weinheim, Germany, 2002).
[0033] When both a basic group and an acid group are present in the
same molecule, the compounds of the invention may also form
internal salts, e.g., zwitterionic molecules.
[0034] Any formula given herein is also intended to represent
unlabeled forms as well as isotopically labeled forms of the
compounds. Isotopically labeled compounds have structures depicted
by the formulas given herein except that one or more atoms are
replaced by an atom having a selected atomic mass or mass number.
Examples of isotopes that can be incorporated into compounds of the
invention include isotopes of hydrogen, carbon, nitrogen, oxygen,
phosphorous, fluorine, and chlorine, such as .sup.2H, .sup.3H,
.sup.11C, .sup.13C, .sup.14C, .sup.15N, .sup.18F .sup.31P,
.sup.32P, .sup.35S, .sup.36Cl, .sup.125I respectively. The
invention includes various isotopically labeled compounds as
defined herein, for example those into which radioactive isotopes,
such as .sup.3H and .sup.14C, or those into which non-radioactive
isotopes, such as .sup.2H and .sup.13C are present. Such
isotopically labelled compounds are useful in metabolic studies
(with .sup.14C), reaction kinetic studies (with, for example
.sup.2H or .sup.3H), detection or imaging techniques, such as
positron emission tomography (PET) or single-photon emission
computed tomography (SPECT) including drug or substrate tissue
distribution assays, or in radioactive treatment of patients. In
particular, an .sup.18F or labeled compound may be particularly
desirable for PET or SPECT studies. Isotopically-labeled compounds
of formula (I) can generally be prepared by conventional techniques
known to those skilled in the art or by processes analogous to
those described in the accompanying Examples and Preparations using
an appropriate isotopically-labeled reagents in place of the
non-labeled reagent previously employed.
[0035] Further, substitution with heavier isotopes, particularly
deuterium (i.e., .sup.2H or D) may afford certain therapeutic
advantages resulting from greater metabolic stability, for example
increased in vivo half-life or reduced dosage requirements or an
improvement in therapeutic index. It is understood that deuterium
in this context is regarded as a substituent of a compound of the
formula (I). The concentration of such a heavier isotope,
specifically deuterium, may be defined by the isotopic enrichment
factor. The term "isotopic enrichment factor" as used herein means
the ratio between the isotopic abundance and the natural abundance
of a specified isotope. If a substituent in a compound of this
invention is denoted deuterium, such compound has an isotopic
enrichment factor for each designated deuterium atom of at least
3500 (52.5% deuterium incorporation at each designated deuterium
atom), at least 4000 (60% deuterium incorporation), at least 4500
(67.5% deuterium incorporation), at least 5000 (75% deuterium
incorporation), at least 5500 (82.5% deuterium incorporation), at
least 6000 (90% deuterium incorporation), at least 6333.3 (95%
deuterium incorporation), at least 6466.7 (97% deuterium
incorporation), at least 6600 (99% deuterium incorporation), or at
least 6633.3 (99.5% deuterium incorporation).
[0036] Pharmaceutically acceptable solvates in accordance with the
invention include those wherein the solvent of crystallization may
be isotopically substituted, e.g. D.sub.2O, d.sub.6-acetone,
d.sub.6-DMSO.
[0037] Compounds of the invention that contain groups capable of
acting as donors and/or acceptors for hydrogen bonds may be capable
of forming co-crystals with suitable co-crystal formers. These
co-crystals may be prepared from compounds of formula (I) by known
co-crystal forming procedures. Such procedures include grinding,
heating, co-subliming, co-melting, or contacting in solution
compounds of formula I with the co-crystal former under
crystallization conditions and isolating co-crystals thereby
formed. Suitable co-crystal formers include those described in WO
2004/078163. Hence the invention further provides co-crystals
comprising a compound of formula (I).
[0038] The invention also provides pro-drugs of the compounds of
the invention that convert in vivo to the compounds of the
invention. A pro-drug is an active or inactive compound that is
modified chemically through in vivo physiological action, such as
hydrolysis, metabolism and the like, into a compound of the
invention following administration of the prodrug to a subject. The
suitability and techniques involved in making and using pro-drugs
are well known by those skilled in the art. See The Practice of
Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San
Diego, Calif., 2001).
[0039] Furthermore, the compounds of the invention, including their
salts, can also be obtained in the form of their hydrates, or
include other solvents used for their crystallization. The
compounds of the invention may inherently or by design form
solvates with pharmaceutically acceptable solvents (including
water); therefore, it is intended that the invention embrace both
solvated and unsolvated forms. The term "solvate" refers to a
molecular complex of a compound of the invention (including
pharmaceutically acceptable salts thereof) with one or more solvent
molecules. Such solvent molecules are those commonly used in the
pharmaceutical art, which are known to be innocuous to the
recipient, e.g., water, ethanol, and the like. The term "hydrate"
refers to the complex where the solvent molecule is water. The
compounds of the invention, including salts, hydrates and solvates
thereof, may inherently or by design form polymorphs.
[0040] Preferred substituents, preferred ranges of numerical values
or preferred ranges of the radicals present in compounds of the
formula I and the corresponding intermediate compounds are defined
below. The definition of the substituents applies to the
end-products as well as to the corresponding intermediates. The
definitions of the substituents may be combined at will, e.g.
preferred substituents A and particularly preferred substituents
R.sub.1.
[0041] In one embodiment, the invention provides a compound of
formula I, wherein R.sub.1 is C.sub.1-6alkyl, C.sub.3-6cycloalkyl,
C.sub.3-6cycloalkyl-C.sub.1-2alkyl.
[0042] In one embodiment, the invention provides a compound of
formula I, wherein R.sub.1 is C.sub.3-4alkyl or
C.sub.3-5cycloalkyl.
[0043] In one embodiment, the invention provides a compound of
formula I, wherein R.sub.1 is isopropyl, cyclopropyl, cyclobutyl or
cyclopentyl.
[0044] In one embodiment, the invention provides a compound of
formula I, wherein R.sub.1 is isopropyl.
[0045] In one embodiment, the invention provides a compound of
formula I, wherein R.sub.1 is cyclobutyl.
[0046] In one embodiment, the invention provides a compound of
formula I, wherein m is 1.
[0047] In one embodiment, the invention provides a compound of
formula I, wherein m is 2.
[0048] In one embodiment, the invention provides a compound of
formula I, wherein n is 0, 1 or 2 and wherein each R.sub.2
independently is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl,
C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or
two R.sub.2 at the same carbon atom form together with said carbon
atom a C.sub.3-4cycloalkyl.
[0049] In one embodiment, the invention provides a compound of
formula I, wherein n is 0.
[0050] In one embodiment, the invention provides a compound of
formula I, wherein X.sub.1 is oxygen.
[0051] In one embodiment, the invention provides a compound of
formula I, wherein X.sub.1 is --N(R.sub.4)-- and R.sub.4 is
hydrogen, C.sub.1-6alkyl, C.sub.3-6cycloalkyl, or
C.sub.3-6cycloalkyl-C.sub.1-2alkyl.
[0052] In one embodiment, the invention provides a compound of
formula I, wherein X.sub.1 is --N(R.sub.4)-- and R.sub.4 is
hydrogen.
[0053] In one embodiment, the invention provides a compound of
formula I, wherein p is 1 and q is 1.
[0054] In one embodiment, the invention provides a compound of
formula I, wherein p is 0 and q is 1.
[0055] In one embodiment, the invention provides a compound of
formula I, wherein p is 0 and q is 0.
[0056] In one embodiment, the invention provides a compound of
formula I, wherein r is 0, 1 or 2 and wherein each R.sub.3
independently is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl,
C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or
two R.sub.3 at the same carbon atom form together with said carbon
atom a C.sub.3-4cycloalkyl.
[0057] In one embodiment, the invention provides a compound of
formula I, wherein r is 0.
[0058] In one embodiment, the invention provides a compound of
formula I, wherein A is A1
##STR00004##
wherein the bond marked with the asterisk is attached to the
nitrogen atom.
[0059] In one embodiment, the invention provides a compound of
formula I, wherein A is A1;
R.sub.5 is hydrogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl or
C.sub.3-4cycloalkyl; s is 0, 1 or 2; and each R.sub.6 independently
is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl.
[0060] In one embodiment, the invention provides a compound of
formula I, wherein A is A1, R.sub.5 is hydrogen or methyl, and s is
0.
[0061] In one embodiment, the invention provides a compound of
formula I, wherein A is A2
##STR00005##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; and s is 0, 1 or 2.
[0062] In one embodiment, the invention provides a compound of
formula I, wherein A is A2;
R.sub.5 is hydrogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl or
C.sub.3-4cycloalkyl; s is 0, 1 or 2; and each R.sub.6 independently
is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl.
[0063] In one embodiment, the invention provides a compound of
formula I, wherein A is A2, R.sub.5 is hydrogen or methyl, and s is
0.
[0064] In one embodiment, the invention provides a compound of
formula I, wherein A is A3
##STR00006##
wherein the bond marked with the asterisk is attached to the
nitrogen atom.
[0065] In one embodiment, the invention provides a compound of
formula I, wherein A is A3;
R.sub.5 is hydrogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl or
C.sub.3-4cycloalkyl; s is 0, 1 or 2; and each R.sub.6 independently
is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl.
[0066] In one embodiment, the invention provides a compound of
formula I, wherein A is A3, R.sub.5 is hydrogen or methyl, and s is
0.
[0067] In one embodiment, the invention provides a compound of
formula I, wherein A is A4
##STR00007##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; and s is 0, 1 or 2.
[0068] In one embodiment, the invention provides a compound of
formula I, wherein A is A4; R.sub.5 is hydrogen, C.sub.1-4alkyl,
C.sub.1-4halogenalkyl or C.sub.3-4cycloalkyl;
s is 0, 1 or 2; and each R.sub.6 independently is halogen,
C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl.
[0069] In one embodiment, the invention provides a compound of
formula I, wherein A is A4, R.sub.5 is hydrogen or methyl, and s is
0.
[0070] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is isopropyl or cyclobutyl; m is 1; n is 0, 1 or 2; each
R.sub.2 independently is halogen, C.sub.1-4alkyl,
C.sub.1-4halogenalkyl, C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or
C.sub.3-4cycloalkyl; or two R.sub.2 at the same carbon atom form
together with said carbon atom a C.sub.3-4cycloalkyl; X.sub.1 is
oxygen; p is 1 and q is 1; r is 0, 1 or 2; wherein each R.sub.3
independently is halogen, C.sub.1-4alkyl, C.sub.1-4halogenalkyl,
C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or
two R.sub.3 at the same carbon atom form together with said carbon
atom a C.sub.3-4cycloalkyl; A is selected from A3 and A4
##STR00008##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; R.sub.5 is hydrogen or methyl; s is 0, 1 or 2; and
each R.sub.6 independently is halogen, C.sub.1-4alkyl,
C.sub.1-4halogenalkyl, C.sub.1-4alkoxy, C.sub.1-4halogenalkoxy or
C.sub.3-4cycloalkyl.
[0071] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is isopropyl or cyclobutyl; m is 1 and n is 0; X.sub.1 is
oxygen;
p is 1 and q is 1; r is 0; and A is
[0072] is selected from A3 and A4
##STR00009##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; and R.sub.5 is hydrogen or methyl; and s is 0.
[0073] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is C.sub.1-6alkyl or C.sub.3-6cycloalkyl; m is 1 and n is
0; X.sub.1 is oxygen; p is 1 and q is 1; r is 0; and
A is
##STR00010##
[0074] wherein the bond marked with the asterisk is attached to the
nitrogen atom; X.sub.2 is nitrogen or carbon; R.sub.5 is hydrogen
or C.sub.1-6alkyl; and s is 0.
[0075] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is C.sub.1-6alkyl or C.sub.3-6cycloalkyl; m is 1 and n is
0; X.sub.1 is oxygen; p is 1 and q is 1; r is 0; and A is selected
from A3 and A4
##STR00011##
wherein the bond marked with the asterisk is attached to the
nitrogen atom; R.sub.5 is hydrogen or C.sub.1-6alkyl; and s is
0.
[0076] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is isopropyl, cyclopropyl or cyclobutyl; m is 1 and n is 0;
X.sub.1 is oxygen; p is 1 and q is 1; r is 0; and
A is
##STR00012##
[0077] wherein the bond marked with the asterisk is attached to the
nitrogen atom; X.sub.2 is nitrogen or carbon; R.sub.5 is hydrogen,
methyl or ethyl; and s is 0.
[0078] In one embodiment, the invention provides a compound of
formula I, wherein
R.sub.1 is isopropyl, cyclopropyl or cyclobutyl; m is 1 and n is 0;
X.sub.1 is oxygen; p is 1 and q is 1; r is 0; and A is is selected
from A3 and A4
##STR00013##
wherein the bond marked with the asterisk is attached to the
nitrogen atom;
[0079] R.sub.5 is hydrogen, methyl or ethyl; and s is 0.
[0080] In preferred embodiments, the invention relates to one or
more than one of the compounds of the formula I mentioned in the
Examples hereinafter or to a salt thereof.
[0081] Further examples of suitable compounds of the invention are
compounds selected from the following group P:
Group P: Suitable Compounds of the Invention:
[0082] 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate; [0083]
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; [0084]
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; [0085]
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclopropylpiperazine-1-carboxylate; [0086]
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate; [0087]
1-(1-ethyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; [0088]
1-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; [0089]
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate; [0090]
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; or [0091]
1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate; [0092] or salts of these
compounds.
[0093] In a further aspect, the invention also provides a process
for the production of compounds of the formula I-1. Compounds of
the formula I-1 are obtainable according to the following process
as described in scheme 1:
##STR00014##
[0094] A compound of formula I-1, in which A, R.sub.1, R.sub.2,
R.sub.3, m, n, p, q and r are as defined under formula I, may be
obtained by reacting a compound of formula II-1, in which A,
R.sub.3, p, q and r are as defined under formula I and R.sub.a is a
leaving group, e.g. halogen, such as chloro, or 4-nitrophenyloxy
(preferably R.sub.a is 4-nitrophenyloxy), with a compound of
formula III, in which R.sub.1, R.sub.2, m and n are as defined
under formula I, in the presence of a suitable base, e.g.
diisopropylethylamine, in the presence of a suitable solvent, e.g.
pyridine.
[0095] In a further aspect, the invention also provides a process
for the production of compounds of the formula I-2. Compounds of
the formula I-2 are obtainable according to the following process
as described in scheme 2:
##STR00015##
[0096] A compound of formula I-2, in which A, R.sub.1, R.sub.2,
R.sub.3, m, n, p, q and r are as defined under formula I, may be
obtained by reacting a compound of formula II-2, in which A,
R.sub.3, p, q and r are as defined under formula I, with a compound
of formula III, in which in which R.sub.1, R.sub.2, m and n are as
defined under formula I, in the presence of carbonyldiimidazole, a
suitable base, e.g. diisopropylethylamine, and a suitable solvent,
e.g. dimethylformamide.
[0097] Further compounds of formula I or their precursors may be
obtainable from compounds of formula I-1 or I-2, prepared as
described according to scheme 1 or 2, or their precursors (e.g.
compounds of formulae II-1, II-2 and/or III) by reduction,
oxidation and/or other functionalization of resulting compounds
and/or by cleavage of any protecting group(s) optionally present,
and of recovering the so obtainable compound of the formula I.
Compounds of the formula I can also be prepared by further
conventional processes, e.g. as described in the Examples, which
processes are further aspects of the invention.
[0098] The invention also contemplates that compounds of formula
(I) may be formed by in vivo biotransformation from pro-drugs.
[0099] The reactions can be effected according to conventional
methods, for example as described in the Examples.
[0100] The work-up of the reaction mixtures and the purification of
the compounds thus obtainable may be carried out in accordance with
known procedures.
[0101] Acid addition salts may be produced from the free bases in
known manner, and vice-versa.
[0102] Starting materials, e.g. compounds of the formulae II-1,
II-2 and III may be known or prepared according to conventional
procedures starting from known compounds, for example as described
in the Examples.
[0103] In a further aspect, the invention also provides a process
for the production of compounds of the formula II-1. Compounds of
the formula II-1 are obtainable according to the following process
as described in scheme 3:
##STR00016##
[0104] Step 3.1:
[0105] A compound of formula V-1, in which A, R.sub.3, p, q and r
are as defined under formula I, may be obtained by reacting a
compound of formula VII-1, in which R.sub.3, p, q and r are as
defined under formula I, with a compound of formula VI, in which A
is as defined under formula I and R.sub.b is halogen, for example
chloro, in the presence of a suitable base, e.g.
diisopropylethylamine, and optionally in the presence of a suitable
solvent.
[0106] Step 3.2:
[0107] A compound of formula II-1, in which A, R.sub.1, R.sub.2,
R.sub.3, m, n, p, q and r are as defined under formula I, may be
obtained by reacting the compound of V-1 with a compound of formula
IV, in which R.sub.c is halogen, for example chloro, and R.sub.a is
a leaving group, e.g. halogen or 4-nitrophenyloxy (preferably
R.sub.a is 4-nitrophenyloxy), in the presence of a suitable base,
e.g. diisopropylethylamine, and in the presence of a suitable
solvent, e.g. pyridine.
[0108] In a further aspect, the invention also provides a novel
compound of formula II-1
##STR00017##
or a salt thereof; in which p, q, r, R.sub.3 and A are as defined
under formula I; R.sub.a is a leaving group, e.g. halogen, such as
chloro, or a group selected from
##STR00018##
wherein the bond marked with the asterisk is attached to the
carbonyl group; wherein R' is hydrogen or nitro; preferably R.sub.a
is 4-nitrophenyloxy.
[0109] In one embodiment of said further aspect, the invention
provides a compound of formula II-1, wherein
p is 1 and q is 1; p is 0 and q is 1; or p is 0 and q is 0; r is 0,
1 or 2 and wherein each R.sub.2 independently is halogen,
C.sub.1-4alkyl, C.sub.1-4halogenalkyl, C.sub.1-4alkoxy,
C.sub.1-4halogenalkoxy or C.sub.3-4cycloalkyl; or two R.sub.2 at
the same carbon atom form together with said carbon atom a
C.sub.3-4cycloalkyl; and
A is A4 or A5.
[0110] In one embodiment of said further aspect, the invention
provides a compound of formula II-1, wherein R.sub.1 is isopropyl;
m is 1; X.sub.1 is oxygen; p is 1 and q is 1; n is 0; p is 1 and q
is 1; A is A4 or A5; and R.sub.5 is hydrogen or methyl,
[0111] In one embodiment of said further aspect, the invention
provides a compound of formula II-1, wherein R.sub.1 is cyclobutyl;
m is 1; X.sub.1 is oxygen; p is 1 and q is 1; n is 0; p is 1 and q
is 1; A is A4 or A5; and R.sub.5 is hydrogen or methyl,
[0112] In another aspect, the invention provides a pharmaceutical
composition comprising a compound of the invention and a
pharmaceutically acceptable carrier. The pharmaceutical composition
can be formulated for particular routes of administration such as
oral administration, parenteral administration, and rectal
administration, etc. In addition, the pharmaceutical compositions
of the invention can be made up in a solid form including capsules,
tablets, pills, granules, powders or suppositories, or in a liquid
form including solutions, suspensions or emulsions. The
pharmaceutical compositions can be subjected to conventional
pharmaceutical operations such as sterilization and/or can contain
conventional inert diluents, lubricating agents, or buffering
agents, as well as adjuvants, such as preservatives, stabilizers,
wetting agents, emulsifers and buffers etc.
[0113] Typically, the pharmaceutical compositions are tablets and
gelatin capsules comprising the active ingredient together with
[0114] a) diluents, e.g., lactose, dextrose, sucrose, mannitol,
sorbitol, cellulose and/or glycine; [0115] b) lubricants, e.g.,
silica, talcum, stearic acid, its magnesium or calcium salt and/or
polyethyleneglycol; for tablets also [0116] c) binders, e.g.,
magnesium aluminum silicate, starch paste, gelatin, tragacanth,
methylcellulose, sodium carboxymethylcellulose and/or
polyvinylpyrrolidone; if desired [0117] d) disintegrants, e.g.,
starches, agar, alginic acid or its sodium salt, or effervescent
mixtures; and/or [0118] e) absorbents, colorants, flavors and
sweeteners.
[0119] Tablets may be either film coated or enteric coated
according to methods known in the art.
[0120] Suitable compositions for oral administration include an
effective amount of a compound of the invention in the form of
tablets, lozenges, aqueous or oily suspensions, dispersible powders
or granules, emulsion, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use are prepared according to any
method known in the art for the manufacture of pharmaceutical
compositions and such compositions can contain one or more agents
selected from the group consisting of sweetening agents, flavoring
agents, coloring agents and preserving agents in order to provide
pharmaceutically elegant and palatable preparations. Tablets
contain the active ingredient in admixture with nontoxic
pharmaceutically acceptable excipients which are suitable for the
manufacture of tablets. These excipients are, for example, inert
diluents, such as calcium carbonate, sodium carbonate, lactose,
calcium phosphate or sodium phosphate; granulating and
disintegrating agents, for example, corn starch, or alginic acid;
binding agents, for example, starch, gelatin or acacia; and
lubricating agents, for example magnesium stearate, stearic acid or
talc. The tablets are uncoated or coated by known techniques to
delay disintegration and absorption in the gastrointestinal tract
and thereby provide a sustained action over a longer period. For
example, a time delay material such as glyceryl monostearate or
glyceryl distearate can be employed. Formulations for oral use can
be presented as hard gelatin capsules wherein the active ingredient
is mixed with an inert solid diluent, for example, calcium
carbonate, calcium phosphate or kaolin, or as soft gelatin capsules
wherein the active ingredient is mixed with water or an oil medium,
for example, peanut oil, liquid paraffin or olive oil.
[0121] Certain injectable compositions are aqueous isotonic
solutions or suspensions, and suppositories are advantageously
prepared from fatty emulsions or suspensions. Said compositions may
be sterilized and/or contain adjuvants, such as preserving,
stabilizing, wetting or emulsifying agents, solution promoters,
salts for regulating the osmotic pressure and/or buffers. In
addition, they may also contain other therapeutically valuable
substances. Said compositions are prepared according to
conventional mixing, granulating or coating methods, respectively,
and contain about 0.1-75%, or contain about 1-50%, of the active
ingredient.
[0122] Suitable compositions for transdermal application include an
effective amount of a compound of the invention with carrier.
Carriers include absorbable pharmacologically acceptable solvents
to assist passage through the skin of the host. For example,
transdermal devices are in the form of a bandage comprising a
backing member, a reservoir containing the compound optionally with
carriers, optionally a rate controlling barrier to deliver the
compound of the skin of the host at a controlled and predetermined
rate over a prolonged period of time, and means to secure the
device to the skin.
[0123] Suitable compositions for topical application, e.g., to the
skin and eyes, include aqueous solutions, suspensions, ointments,
creams, gels or sprayable formulations, e.g., for delivery by
aerosol or the like. Such topical delivery systems will in
particular be appropriate for dermal application, e.g., for the
treatment of skin cancer, e.g., for prophylactic use in sun creams,
lotions, sprays and the like. They are thus particularly suited for
use in topical, including cosmetic, formulations well-known in the
art. Such may contain solubilizers, stabilizers, tonicity enhancing
agents, buffers and preservatives.
[0124] As used herein a topical application may also pertain to an
inhalation or to an intranasal application. They are conveniently
delivered in the form of a dry powder (either alone, as a mixture,
for example a dry blend with lactose, or a mixed component
particle, for example with phospholipids) from a dry powder inhaler
or an aerosol spray presentation from a pressurised container,
pump, spray, atomizer or nebuliser, with or without the use of a
suitable propellant.
[0125] The invention further provides anhydrous pharmaceutical
compositions and dosage forms comprising the compounds of the
invention as active ingredients, since water may facilitate the
degradation of certain compounds.
[0126] Anhydrous pharmaceutical compositions and dosage forms of
the invention can be prepared using anhydrous or low moisture
containing ingredients and low moisture or low humidity conditions.
An anhydrous pharmaceutical composition may be prepared and stored
such that its anhydrous nature is maintained. Accordingly,
anhydrous compositions are preferably packaged using materials
known to prevent exposure to water such that they can be included
in suitable formulary kits. Examples of suitable packaging include,
but are not limited to, hermetically sealed foils, plastics, unit
dose containers (e.g., vials), blister packs, and strip packs.
[0127] The invention further provides pharmaceutical compositions
and dosage forms that comprise one or more agents that reduce the
rate by which the compound of the invention as an active ingredient
will decompose. Such agents, which are referred to herein as
"stabilizers," include, but are not limited to, antioxidants such
as ascorbic acid, pH buffers, or salt buffers, etc.
[0128] As used herein, the term "pharmaceutically acceptable
carrier" includes any and all solvents, dispersion media, coatings,
surfactants, antioxidants, preservatives (e.g., antibacterial
agents, antifungal agents), isotonic agents, absorption delaying
agents, salts, preservatives, drugs, drug stabilizers, binders,
excipients, disintegration agents, lubricants, sweetening agents,
flavoring agents, dyes, such like materials and combinations
thereof, as would be known to one of ordinary skill in the art
(see, for example, Remington's Pharmaceutical Sciences, 18th Ed.
Mack Printing Company, 1990, pp. 1289-1329). Except insofar as any
conventional carrier is incompatible with the active ingredient,
its use in the therapeutic or pharmaceutical compositions is
contemplated.
[0129] The compounds of formula I or pharmaceutical acceptable
salts thereof exhibit valuable pharmacological properties and are
therefore useful as pharmaceuticals.
[0130] Furthermore, compounds of formula I may be useful for
research on H3 receptors, e.g. as tool compounds.
[0131] In particular, compounds of formula I exhibit a H3 receptor
antagonistic action at human H3 receptors.
[0132] As used herein, the term "H3 receptor antagonist"
encompasses H3 receptor inverse agonists and H3 receptor neutral
antagonists.
[0133] H3 receptor antagonistic action can be determined in vitro,
for example, at recombinant human H3 receptors, using different
procedures like, for example, measurement of the inhibition of the
agonist induced elevation of intracellular cAMP concentration, e.g.
as described herein.
[0134] The compounds of the invention may be therefore useful in
the prevention, treatment or delay of progression of disorders
mediated by H3 receptors.
[0135] Disorders mediated by H3 receptors may be for example
i) disorders of sleep and wakefulness with excessive daytime
sleepiness; such as narcolepsy, e.g. narcolepsy with or without
cataplexy; secondary narcoleptic syndromes; central sleep apnea
syndrome; or obstructive sleep apnea syndrome; ii) disorders or
conditions associated with increased fatigue or hypersomnolence;
such as fatigue associated with autoimmune disease, e.g. Multiple
Sclerosis or Rheumatoid Arthritis; fatigue associated with
neurodegenerative disorders, e.g. as Parkinson's disease,
Multisystem atrophy, Shy-Drager-Syndrome or Progressive
Supranuclear Palsy; fatigue associated with other medical
conditions or their treatment, such as depression, burnout
syndrome, or adjustment disorder; stress-associated disorders with
fatigue, e.g. acute stress disorder or posttraumatic stress
disorder; cancer-associated fatigue; chemotherapy-associated
fatigue; fatigue associated with shift-work; jet lag; chronic
fatigue syndrome; fibromyalgia; postinfectious fatigue;
postoperative fatigue or dizziness; iii) disorders or conditions
with impaired cognition; such as Alzheimers Disease; Mild Cognitive
Impairment; Diffuse-Lewy body dementia; vascular dementia;
Huntington's disease; Wilson's disease; frontotemporal dementia;
other forms of organic dementia or organic cognitive impairment;
multiple sclerosis; schizophenia; schizoaffective disorder;
bipolar-affective disorder; iv) disorders of substance abuse or
addiction; such as to alcohol, cocaine, opioids, cannabinoids,
nicotine or other substances with abuse or addiction potential; v)
non-substance abuse conditions; such as pathological gambling; vi)
disorders associated with dysfunctional feeding behaviours and/or
metabolic syndome; such as antipsychotic drug-associated weight
gain; Prader-Willi-Sndrome; Moon-Bardet-Biedl Syndrome; obesity;
atypical depression; bulimia nervosa; or binge eating disorder;
vii) disorders with increased anxiety; such as general anxiety
disorder; social anxiety disorder; or panic disorder; viii) other
neuropsychiatric or neurological disorders; such as Tourette
syndrome; primary tic disorders; secondary tic disorders; attention
deficit hyperactivity disorders; obesessive-compulsive disorders;
headache disorders, e.g. episodic migraine, chronic migraine,
cluster headache, or tension-type headache; acute disordes
associated with neuronal loss, e.g. stroke; REM-sleep behavioural
disorder; restless-legs syndrome; or epilepsy; ix) other medical
conditions or disorders; such as disorders with impaired hearing;
vertigo; Menieres Disease; itch; pruritus; inflammatory pain;
neuropathic pain; diabetes mellitus; cancer; atherosclerosis;
allergies; or allergic rhinitis;
[0136] Of particular importance is the treatment of narcolepsy;
fatigue associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; or
Attention-deficit hyperactivity disorder.
[0137] For the above-mentioned indications (the conditions and
disorders) the appropriate dosage will vary depending upon, for
example, the compound employed, the host, the mode of
administration and the nature and severity of the condition being
treated. However, in general, satisfactory results in animals are
indicated to be obtained at a daily dosage of from about 0.001 to
about 500 mg/kg body weight, preferably from about 0.1 to about 10
mg/kg body weight, e.g. 1 mg/kg. In larger mammals, for example
humans, an indicated daily dosage is in the range from about 0.1 to
about 1000 mg, preferably from about 0.1 to about 400 mg, most
preferably from about 0.1 to about 100 mg of the compound of the
invention conveniently administered, for example, in divided doses
up to four times a day.
[0138] For use according to the invention, a compound of the
invention may be administered as single active agent or in
combination with other active agents, in any usual manner, e.g.
orally, for example in the form of tablets or capsules, or
parenterally, for example in the form of injection solutions or
suspensions. A combination comprising a compound of the invention
and one or more other therapeutically active agents will be
referred to as "combination of the invention".
[0139] In the case of narcolepsy, the compound of the invention may
be combined at least with one active agent selected from the group
consisting of
a noradrenaline-dopamine reuptake inhibitor, such as modafinil or
armodafinil; a tri- or tetracyclic antidepressant, such as
clomipramine; a serotonin-noradrenaline reuptake inhibitor, such as
venlafaxine or duloxetine; a selective serotonin reuptake
inhibitor, such as paroxetine; a noradrenaline reuptake inhibitor,
such as reboxetine or atomoxetine; a MAO-B inhibitor such as
selegiline; a gamma-hydroxy-butyrate; and a psychostimulant, such
as methylphenidate.
[0140] Said combination of the invention is useful to treat
narcolepsy.
[0141] In the case of fatigue associated with multiple sclerosis,
the compound of the invention may be combined at least with one
active agent selected from the group consisting of
a sphingosine-1-phosphate analog, such as fingolimod; and another
immunosuppressive agent, such as prednisolone or methotrexate.
[0142] In the case of fatigue associated with Parkinson's disease,
the compound of the invention may be combined at least with one
active agent selected from the group consisting of
L-Dopa with or without a Decarboxylase inhibitor, such as
Benzerazid or Carbidopa, and/or with or without a
catechol-O-Methytransferase inhibitor, such as entacapone or
tolcapone; a dopamine receptor agonist, such as ropinirole or
pergolide; and a MAO-B inhibitor, such as selegiline.
[0143] In the case of cognitive impairment associated with
schizophrenia, the compound of the invention may be combined at
least with one antipsychotic agent, such as haloperidol,
olanzapine; risperidone; quetiapine; amisulpiride; or
aripirazole.
[0144] In the case of cognitive impairment associated with
Alzheimer's disease, the compound of the invention may be combined
at least with one active agent selected from the group consisting
of
a cholinergic agent, such as an acetylcholinesterase inhibitor,e.g.
donepezil, rivastigmine or galantamine; and an antiglutamatergic
agent, such as memantine, selfotel or midafotel.
[0145] In the case of cognitive impairment associated with
Alzheimer's disease, the compound of the invention may be combined
at least with one active agent selected from the group consisting
of
a cholinergic agent, such as an acetylcholinesterase inhibitor,e.g.
donepezil, rivastigmine or galantamine; and an antiglutamatergic
agent, such as memantine.
[0146] In the case of Tourette's syndrome, the compound of the
invention may be combined at least with one active agent selected
from the group consisting of
an alpha receptor agonist, such as clonidine; an antipsychotic
agent, such as fluphenazine, haloperidol, pimozide, aripirazole, of
risperidone; and a dopamine depleting agent, such as
tetrabenazine.
[0147] In the case of attention-deficit hyperactivity disorder, the
compound of the invention may be combined at least with one active
agent selected from the group consisting of
a noradrenaline-dopamine reuptake inhibitor, such as modafinil or
armodafinil; a tri- or tetracyclic antidepressant, such as
clomipramine; a psychostimulant, such as methylphenidate a
noradrenaline-serotonin reuptake inhibitor, such as venlafaxine or
duloxetine; a selective serotonin reuptake inhibitor, such as
paroxetine; and a noradrenaline reuptake inhibitor, such as
reboxetine or atomoxetine.
[0148] The compounds of the invention may be useful for the
prevention of the above-mentioned conditions and disorders.
[0149] The compounds of the invention may be useful for the
treatment of the above-mentioned conditions and disorders.
[0150] The compounds of the invention may be useful for the delay
of progression of the above-mentioned conditions and disorders.
[0151] The usefulness of the compounds of the invention in the
treatment of the above-mentioned disorders can be confirmed in a
range of standard tests including those indicated below:
[0152] The in vivo activity of the compounds of the invention can
be assessed by measuring the effects on brain histamine release
(quantification of the histamine metabolite tele-methylhistamine)
and/or by testing the effects on wakefulness in rats with EEG
electrodes.
[0153] Compounds of the invention may be especially useful in the
treatment of an indication selected from: narcolepsy; fatigue
associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; and
Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0154] Thus, as a further embodiment, the invention provides the
use of a compound of formula (I) or a pharmaceutically acceptable
salt thereof as a medicament.
[0155] As a further embodiment, the invention provides the use of a
compound of formula (I) or a pharmaceutically acceptable salt
thereof in therapy.
[0156] In a further embodiment, the therapy is selected from a
disease which is ameliorated by inhibition of H3 receptor action.
In another embodiment, the disease is selected from the
afore-mentioned list, e.g. is selected from narcolepsy; fatigue
associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; and
Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0157] In another embodiment, the invention provides a method of
treating a disease which is ameliorated by inhibition of H3
receptors comprising administration of a therapeutically acceptable
amount of a compound of formula (I) or a pharmaceutically
acceptable salt thereof. In a further embodiment, the disease is
selected from the afore-mentioned list, e.g. is selected from
narcolepsy; fatigue associated with multiple sclerosis; fatigue
associated with Parkinson's disease; cognitive impairment
associated with schizophrenia; cognitive impairment associated with
Alzheimer's disease; mild cognitive impairment; Tourette syndrome;
and Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0158] The term "a therapeutically effective amount" of a compound
of the invention refers to an amount of the compound of the
invention that will elicit the biological or medical response of a
subject, for example, reduction or inhibition of an enzyme or a
protein activity, or ameliorate symptoms, alleviate conditions,
slow or delay disease progression, or prevent a disease, etc. In
one non-limiting embodiment, the term "a therapeutically effective
amount" refers to the amount of the compound of the invention that,
when administered to a subject, is effective to (1) at least
partially alleviating, inhibiting, preventing and/or ameliorating a
condition, or a disorder or a disease (i) mediated by H3 receptors,
or (ii) associated with H3 receptor activity, or (iii)
characterized by abnormal activity of H3 receptors; or (2) reducing
or inhibiting the activity of H3 receptors; or (3) reducing or
inhibiting the expression of H3 receptors. In another non-limiting
embodiment, the term "a therapeutically effective amount" refers to
the amount of the compound of the invention that, when administered
to a cell, or a tissue, or a non-cellular biological material, or a
medium, is effective to at least partially reducing or inhibiting
the activity of H3 receptors; or at least partially reducing or
inhibiting the expression of H3 receptors.
[0159] As used herein, the term "subject" refers to an animal.
Preferably, the animal is a mammal. A subject also refers to for
example, primates (e.g., humans), cows, sheep, goats, horses, dogs,
cats, rabbits, rats, mice, fish, birds and the like. In a preferred
embodiment, the subject is a human.
[0160] As used herein, the term "inhibition" or "inhibiting" refers
to the reduction or suppression of a given condition, symptom, or
disorder, or disease, or a significant decrease in the baseline
activity of a biological activity or process.
[0161] As used herein, the term "treating" or "treatment" of any
disease or disorder refers in one embodiment, to ameliorating the
disease or disorder (i.e., slowing or arresting or reducing the
development of the disease or at least one of the clinical symptoms
thereof). In another embodiment "treating" or "treatment" refers to
alleviating or ameliorating at least one physical parameter
including those which may not be discernible by the patient. In yet
another embodiment, "treating" or "treatment" refers to modulating
the disease or disorder, either physically, (e.g., stabilization of
a discernible symptom), physiologically, (e.g., stabilization of a
physical parameter), or both. In yet another embodiment, "treating"
or "treatment" refers to preventing or delaying the onset or
development or progression of the disease or disorder.
[0162] The pharmaceutical composition or combination of the
invention can be in unit dosage of about 1-1000 mg of active
ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or
about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50
mg of active ingredients. The therapeutically effective dosage of a
compound, the pharmaceutical composition, or the combinations
thereof, is dependent on the species of the subject, the body
weight, age and individual condition, the disorder or disease or
the severity thereof being treated. A physician, clinician or
veterinarian of ordinary skill can readily determine the effective
amount of each of the active ingredients necessary to prevent,
treat or inhibit the progress of the disorder or disease.
[0163] The above-cited dosage properties are demonstrable in vitro
and in vivo tests using advantageously mammals, e.g., mice, rats,
dogs, monkeys or isolated organs, tissues and preparations thereof.
The compounds of the invention can be applied in vitro in the form
of solutions, e.g., preferably aqueous solutions, and in vivo
either enterally, parenterally, advantageously intravenously, e.g.,
as a suspension or in aqueous solution. The dosage in vitro may
range between about 10.sup.-3 molar and 10.sup.-9 molar
concentrations. A therapeutically effective amount in vivo may
range depending on the route of administration, between e.g. about
0.001-500 mg/kg, or between e.g. about 0.1-100 mg/kg.
[0164] The activity of a compound of the invention can be assessed
by in vitro & in vivo methods described herein.
[0165] The compound of the invention may be administered either
simultaneously with, or before or after, at least one other
therapeutic agent. The compound of the invention may be
administered separately, by the same or different route of
administration, or together in the same pharmaceutical
composition.
[0166] The following Examples illustrate the invention, but do not
limit it.
ABBREVIATIONS
[0167] BINAP (+/-)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl
[0168] Boc di(tert-butyl) carbonate [0169] BTC triphosgene [0170]
DCM dichloromethane [0171] DIPEA N-ethyl-N-isopropylpropan-2-amine
(Diisopropylethylamine) [0172] DMAP 4-Dimethylaminepyridine [0173]
EA ethyl acetate [0174] h hour(s) [0175] HPLC high pressure liquid
chromatography [0176] LCMS liquid chromatography mass spectroscopy
[0177] MeOH methanol [0178] min minute(s) [0179] NMR nuclear
magnetic resonance spectrometry [0180] prep-HPLC preparative high
pressure liquid chromatography [0181] Pd.sub.2(dba).sub.3
tris(dibenzylideneacetone)dipalladium(0) [0182] Rt retention time
[0183] rt room temperature [0184] t-BuOK Potassium tert-butanolate
[0185] TEA triethylamine [0186] TFA trifluoroacetic acid [0187] THF
tetrahydrofuran
[0188] LCMS conditions (%=percent by volume): Agilent 1200
HPLC/6110 SQ system; Mobile Phase: A: water (10 mM
NH.sub.4HCO.sub.3) B: Acetonitrile; Gradient: 5% B for 0.2 min,
increase to 95% B within 1.2 min; 95% B for 1.5 min, back to 5% B
within 0.01 min; Flow Rate: 1.8 ml/min; Column: XBridge C18, 4.6*50
mm, 3.5 .mu.m; Oven Temperature: 50.degree. C.
[0189] .sup.1H NMR Instruments: Bruker AVANCE III (500 MHz), Bruker
AVANCE III (400 MHz)
EXAMPLES
Example 1.1
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl 4-cyclobutyl
piperazine-1-carboxylate (Method A)
##STR00019##
[0190] a) tert-butyl 4-cyclobutylpiperazine-1-carboxylate
##STR00020##
[0192] To a solution of compound tert-butyl
piperazine-1-carboxylate (37.2 g, 200 mmol) in ClCH.sub.2CH.sub.2Cl
(500 mL) was added cyclobutanone (21 g, 300 mmol) and
NaBH(OAc).sub.3 (84.8 g, 400 mmol). The reaction mixture was
stirred at rt for 16 h, quenched with saturated aq.
Na.sub.2CO.sub.3 (500 mL) and extracted with DCM (3.times.500 mL).
The combined organic layers were washed with brine (50 mL), dried,
filtered and concentrated under reduced pressure to afford the
desired compound tert-butyl 4-cyclobutylpiperazine-1-carboxylate
(48 g, 100%) [LCMS: Rt=1.67 min, m/z 241.2 (M+H).sup.+].
b) 1-cyclobutylpiperazine hydrochloride
##STR00021##
[0194] To the mixture of tert-butyl
4-cyclobutylpiperazine-1-carboxylate (48 g, 200 mmol) in MeOH (100
mL) was added 2.0 M HCl in MeOH (400 mL) carefully at 0.degree. C.
The mixture was stirred at rt for 5 h, concentrated under reduced
pressure to afford the desired compound 1-cyclobutylpiperazine
hydrochloride (35 g, 82%) [LCMS: Rt=0.94 min, m/z 141.3
(M+H).sup.+].
c) 6-(4-hydroxypiperidin-1-yl)pyridazin-3(2H)-one
##STR00022##
[0196] To a solution of 6-chloropyridazin-3(2H)-one (2.6 g, 20
mmol) in DIPEA (30 mL) was added piperidin-4-ol (2.4 g, 20 mmol)
and the mixture was stirred at 120.degree. C. for 8 h. The reaction
mixture was concentrated under reduced pressure to afford the crude
product, which was further purified by silica gel chromatography
(DCM/MeOH=20/1) to afford the title compound (3.9 g, 100%) as a
yellow solid. [LCMS: Rt=0.77 min, m/z 196.2 (M+H).sup.+].
d) 4-nitrophenyl 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
carbonate
##STR00023##
[0198] To a solution of
6-(4-hydroxypiperidin-1-yl)pyridazin-3(2H)-one (3.9 g, 20 mmol) in
pyridine (10 mL) was added DIPEA (3.87 g, 30.0 mmol) and
4-nitrophenyl carbonochloridate (6.03 g, 30 mmol) and the resulting
mixture was stirred at 30.degree. C. for 2 h. The mixture was
concentrated under reduced pressure and the residue was purified by
silica gel chromatography (DCM to DCM/MeOH=20/1) to afford the
title compound (3.3 g, 46%) as a white solid. [LCMS: Rt=1.47 min,
m/z 361.1 (M+H).sup.+].
e) 1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate
##STR00024##
[0200] To a solution of 4-nitrophenyl
1-(6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl carbonate (440
mg, 1.22 mmol) in DCM (20 mL) was added TEA (616 mg, 6.1 mmol) and
1-cyclobutylpiperazine (388 mg, 1.83 mmol). The resulting mixture
was stirred at 30.degree. C. for 2 h before it was concentrated to
dryness. The title compound was obtained as a white solid after
silica gel chromatography (DCM/MeOH=50/1 to 5/1) (410 mg, 93%). CH
NMR (400 MHz, CDCl.sub.3) .delta. 11.20 (s, 1H), 7.20 (d, J=10 Hz,
1H), 6.87 (d, J=10 Hz, 1H), 4.87.about.4.92 (m, 1H),
3.45.about.3.50 (m, 6H), 3.16.about.3.23 (m, 2H), 2.68.about.2.76
(m, 1H), 2.29 (br, 4H), 1.72.about.2.07 (m, 10H); LCMS: Rt=1.36
min, m/z 362.3 (M+H).sup.+].
Example 1.2
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl-4-isopropylpipe-
razine-1-carboxylate
##STR00025##
[0201] a) 6-chloro-2-methylpyridazin-3(2H)-one
##STR00026##
[0203] To a solution of 6-chloropyridazin-3(2H)-one (780 mg, 6
mmol) in CH.sub.3CN (40 mL) was added Cs.sub.2CO.sub.3 (3.9 g, 12
mmol) and CH.sub.3I (1 mL, 12 mmol) and the reaction mixture was
stirred at 70.degree. C. overnight. Solid was removed by filtration
and the filtrate was concentrated under reduced pressure. The
residue was purified by silica gel chromatography (hexane/EA=3/1)
to afford the title compound as orange oil (6.5 g, 75%). [LCMS:
Rt=1.43 min, m/z 145.1 (M+H).sup.+].
b) 6-(4-hydroxypiperidin-1-yl)-2-methylpyridazin-3(2H)-one
##STR00027##
[0205] To a slurry of 6-chloro-2-methylpyridazin-3(2H)-one (1 g,
6.94 mmol) in DIPEA (20 mL) was added piperidin-4-ol (0.84 g, 8.33
mmol) and the reaction mixture was stirred at 120.degree. C.
overnight. The resulting mixture was diluted with water (30 mL) and
extracted with DCM (3.times.30 mL) to remove impurities. The
aqueous phase was concentrated to dryness to afford the title
compound as a yellow solid (1.2 g, 83%). [LCMS: Rt=1.07 min, m/z
210.1 (M+H).sup.+].
c)
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl-4-nitropheny-
l carbonate
##STR00028##
[0207] To a solution of
6-(4-hydroxypiperidin-1-yl)-2-methylpyridazin-3(2H)-one (1.46 g, 7
mmol) in DCM (20 mL) was added 4-nitrophenyl carbonochloridate
(2.11 g, 10.5 mmol) and DIPEA (1.81 g, 14 mmol) and the mixture was
stirred at rt overnight. The mixture was diluted with DCM (20 mL),
washed with water (3.times.15 mL) and the organic layer was
concentrated to afford the title compound as a yellow solid (1.2 g,
46%). [LCMS: Rt=1.54 min, m/z=375.1 (M+H).sup.+].
d)
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl-4-isopropylp-
iperazine-1-carboxylate
##STR00029##
[0209] To a solution of 1-(1-methyl-6-oxo-1,
6-dihydropyridazin-3-yl)piperidin-4-yl 4-nitrophenyl carbonate (1.2
g, 3.2 mmol) in DCM (20 mL) was added 1-isopropylpiperazine (0.6 g,
4.8 mmol) and TEA (5 mL) and the reaction mixture was stirred at rt
overnight. The mixture was then washed with saturated
Na.sub.2CO.sub.3 (3.times.30 mL), dried and concentrated to give
crude product, which was purified by silica gel chromatography
(PE/EA=1/1) to afford the title compound as a white solid (0.48 g,
41%). CH NMR (CDCl.sub.3, 400 MHz): .delta.7.13.about.7.10 (d,
J=10, 1H), 6.86.about.6.84 (d, J=10, 1H), 4.92.about.4.88 (m, 1H),
3.66 (s, 3H), 3.51.about.3.46 (br, 6H); 3.22.about.3.16 (m, 2H);
2.74.about.2.70 (m, 1H), 2.49 (br, 4H), 1.99 (m, 2H), 1.75 (m, 2H),
1.04 (d, 6H); LCMS Rt=1.40 min, m/z 364.2 (M+H).sup.+].
Example 1.5
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate
##STR00030##
[0210] a)
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-piperidin-4-yl-4-cy-
clobutyl-piperazine-1-carboxylate
##STR00031##
[0212] To a solution of 1-(1-methyl-6-oxo-1,
6-dihydropyridazin-3-yl) piperidin-4-yl 4-nitrophenyl carbonate
(101 mg, 0.27 mmol) in 8 mL of DCM, was added DIEA (105 mg, 0.81
mmol) and 1-cyclobutylpiperazine (56 mg, 0.40 mmol). The mixture
was stirred at rt over night before it was diluted with 30 mL of
water, extracted with DCM (3*25 mL). The combined organic phase was
dried over anhydrous Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure. The residue was purified via Flash
(Biotage, reversed phase column C-18, MeOH/H.sub.2O=5%-95%, 0.5%
NH.sub.4OH) to afford 20 mg of the desired compound as a white
solid. [.sup.1H NMR (CDCl.sub.3, 400 MHz): .delta.7.12 (d, J=10,
1H), 6.85 (d, J=10, 1H), 4.94-4.88 (m, 1H), 3.67 (s, 3H), 3.52-3.46
(m, 6H), 3.23-3.17 (m, 2H), 2.75-2.69 (m, 1H), 2.30 (b, 4H),
2.08-1.97 (m, 4H), 1.93-1.86 (m, 2H), 1.82-1.68 (m, 4H); LCMS
Rt=1.44 min, m/z 376.3 (M+H).sup.+].
Example 2
Synthesis of
1-(1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)piperidin-4-yl-4-isopropylpip-
erazine-1-carboxylate (Method B)
##STR00032##
[0213] a) tert-butyl 4-hydroxypiperidine-1-carboxylate
##STR00033##
[0215] To a solution of tert-butyl 4-oxopiperidine-1-carboxylate
(10 g, 50 mmol) in CH.sub.3OH (100 mL) was added NaBH.sub.4 (5.7 g,
150 mmol) portionwise carefully and the mixture was stirred at rt
for 3 h. The reaction was quenched by carefully pouring into
ice-water (100 mL) and organic solvent was removed under reduced
pressure. The aqueous phase was neutralized to pH=7 with 1N HCl and
extracted with DCM/MeOH (5.times.60 mL, v/v=10/1). The combined
organic layers were washed with brine (30 mL), dried over anhydrous
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to afford the crude product (9.8 g, 97%) as a white solid. [LCMS:
Rt=1.36 min, m/z 146.1 (M-Bu+H).sup.+].
a) 1-(tert-butoxycarbonyl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate
##STR00034##
[0217] To a solution of tert-butyl
4-hydroxypiperidine-1-carboxylate (4.4 g, 21.9 mmol) in DCM (100
mL) was carefully added DMAP (5.3 g, 43.8 mmol) and triphosgene
(3.2 g, 10.95 mmol) portionwise. After stirring at rt for 2 h,
1-isopropylpiperazine (3.3 g, 26 mmol) was added and the reaction
mixture was stirred at rt for 5 h. The reaction was quenched with
saturated NH.sub.4Cl (100 mL) solution and the mixture was
extracted with DCM (3.times.100 mL). The combined organic layers
were washed with saturated NH.sub.4Cl (2.times.100 mL) and brine
(50 mL) sequentially, dried over anhydrous Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to afford the
title compound as a white solid (7.7 g, 99%). [LCMS: Rt=1.67 min,
m/z 356.3 (M+H).sup.+].
b) piperidin-4-yl 4-isopropylpiperazine-1-carboxylate
##STR00035##
[0219] To a solution of 1-(tert-butoxycarbonyl)piperidin-4-yl
4-isopropyl piperazine-1-carboxylate (7.7 g, 21.7 mmol) in DCM (30
mL) was added TFA (10 mL) and the reaction mixture was stirred at
rt for 5 h. The solvent was removed under reduced pressure and the
residue was re-dissolved in DCM/MeOH (100 mL, v/v=10/1). Then
powder Na.sub.2CO.sub.3 was added and the mixture was stirred at rt
for 2 h. Excess Na.sub.2CO.sub.3 was removed by filtration and the
cake was washed with DCM (2.times.100 mL). The combined filtrates
were concentrated under reduced pressure to afford the desired
compound as yellow oil (5.5 g, 100%). [LCMS: Rt=1.12 min, m/z 256.2
(M+H).sup.+].
c)
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl-4-isopropylpiperazine-1-
-carboxylate
##STR00036##
[0221] To a solution of 4-bromopyridin-2(1H)-one (173 mg, 1.0 mmol)
in TEA (10 mL) was added
piperidin-4-yl-4-isopropylpiperazine-1-carboxylate (255 mg, 1.0
mmol) and the mixture was stirred at 100.degree. C. for 16 h. After
cooling to rt, the mixture was concentrated under vacuum. The
residue was dissolved in DCM (50 mL) and the mixture was washed
with saturated NaHCO.sub.3 solution (2.times.30 mL). The organic
layer was dried and concentrated to afford the crude product (348
mg, 100%), which was used directly for next step without further
purification. [LCMS: Rt=1.27 min, m/z 349.2 (M+H).sup.+]. [0222] d)
1-(1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)piperidin-4-yl-4-isopropylpip-
erazine-1-carboxylate
##STR00037##
[0223] To a solution of
1-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate (348 mg, 1.0 mmol) in THF (10
mL) was added NaH (60% in mineral oil) (200 mg, 5.0 mmol)
portionwise. After stirring at rt for 1 h, CH.sub.3I (213 mg, 1.5
mmol) was added and the reaction mixture was stirred at rt for 5 h.
The reaction was quenched with water (30 mL), extracted with DCM
(3.times.30 mL), dried and concentrated to give crude product,
which was further purified by prep-HPLC to afford the title
compound as a white solid (110 mg, 30%). CH NMR (500 MHz,
CDCl.sub.3) .delta. 7.07 (d, J=8.0 Hz, 1H), 5.90 (dd, J=8.0, 2.5
Hz, 1H), 5.77 (d, J=2.5 Hz, 1H), 4.89.about.4.94 (m, 1H),
3.47.about.3.52 (m, 6H), 3.44 (s, 3H), 3.20.about.3.25 (m, 2H),
2.68.about.2.73 (m, 1H), 2.47 (br, 4H), 1.92.about.1.98 (m, 2H),
1.69.about.1.76 (m, 2H), 1.04 (d, J=6.5 Hz, 6H); LCMS: Rt=1.31 min,
m/z 363.3 (M+H).sup.+].
Example 3
1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl-4-isopropylpiperazine-1-ca-
rboxylate (Method C)
##STR00038##
[0224] a) 2-(benzyloxy)-5-bromopyridine
##STR00039##
[0226] To a solution of 5-bromopyridin-2(1H)-one (1.28 g, 7.36
mmol) and Ag.sub.2CO.sub.3 (3 g, 11.04 mmol) in toluene (50 mL) was
added (bromomethyl)benzene (1.25 g, 7.36 mmol) dropwise and the
reaction mixture was stirred at 100.degree. C. over night. The
reaction mixture was filtered through a short pad of silica gel and
washed with DCM. The filtrate was concentrated to yield the title
compound as light yellow oil (1.8 g, 95%).
b) 1-(6-(benzyloxy)pyridin-3-yl)piperidin-4-yl
4-isopropylpiperazine-1-carboxylate
##STR00040##
[0228] To a solution of 2-(benzyloxy)-5-bromopyridine (1.5 g, 5.6
mmol), piperidin-4-yl 4-isopropylpiperazine-1-carboxylate (2.15 g,
8.4 mmol) in toluene (30 mL) was added Pd.sub.2(dba).sub.3 (1.57 g,
2.2 mmol), BINAP (2.79 g, 4.4 mmol) and t-BuOK (3.78 g, 33.8 mmol).
The reaction was stirred under the microwave irradiation at
120.degree. C. for 20 min. The mixture was diluted with EA (100 mL)
and washed with water (3.times.50 mL). The organic phase was
separated, dried and concentrated to dryness. The residue was taken
into dilute HCl (pH=1, 100 mL) and the mixture was extracted with
DCM (3.times.100 mL) to remove impurities. The aqueous phase was
made basic (pH=9-10) with solid Na.sub.2CO.sub.3 and extracted with
DCM (3.times.100 mL). The combined organic layers were dried,
concentrated and purified by silica gel chromatography
(EA/MeOH=50/1) to give the title compound as a white solid (500 mg,
20%). [LCMS: Rt=2.09 mim, m/z 439.3 (M+H)+].
c)
1-(6-oxo-1,6-dihydropyridin-3-yl)piperidin-4-yl-4-isopropylpiperazine-1-
-carboxylate
##STR00041##
[0230] To a suspension of
1-(6-(benzyloxy)pyridin-3-yl)-piperidin-4-yl-4-isopropylpiperazine-1-carb-
oxylate (200 mg, 0.46 mmol) in MeOH (10 mL) was added 10% Pd/C (200
mg) and the mixture was hydrogenated (hydrogen balloon) at rt for
10 min. The catalyst was removed by filtering through Celite.RTM.
and the filtrate was concentrated under vacuum. The desired product
was obtained as a white solid after pre-HPLC purification (40 mg,
25%). CH NMR (400 MHz, MeOD-d.sub.4) .delta. 7.50 (dd, J=10 Hz,
J.sub.2=3.2 Hz, 1H), 6.81 (d, J=3.2 Hz, 1H), 6.41 (d, J=10 Hz, 1H),
4.68 (m, 1H), 3.45 (br, 4H), 3.00 (m, 2H), 2.75 (m, 3H), 2.59 (m,
4H), 1.90 (m, 2H), 1.70 (m, 2H), 1.02 (d, J=6.4 Hz, 6H); LCMS:
Rt=1.37 min, m/z 349.2 (M+H).sup.+].
[0231] Table 1 shows compounds of formula (I). Examples 1.1 to 1.6
were synthesized according to Method A; Examples 2.1 to 2.3 were
synthesized according to Method B; Example 3.1 was synthesized
according to Method C.
TABLE-US-00001 TABLE 1 LCMS Rt [min], Ex. Structure Name method [M
+ H].sup.+ 1.1 ##STR00042## 1-(6-oxo-1,6-dihydropyridazin-3-
yl)piperidin-4-yl 4- cyclobutylpiperazine-1- carboxylate 1.65(A)
362.2 1.2 ##STR00043## 1-(1-methyl-6-oxo-1,6-
dihydropyridazin-3-yl)piperidin- 4-yl 4-isopropylpiperazine-1-
carboxylate 1.4(A) 364.2 1.3 ##STR00044##
1-(6-oxo-1,6-dihydropyridazin-3- yl)piperidin-4-yl 4-
isopropylpiperazine-1- carboxylate 1.33(A) 350.2 1.4 ##STR00045##
1-(6-oxo-1,6-dihydropyridazin-3- yl)piperidin-4-yl 4-
cyclopropylpiperazine-1- carboxylate 1.05(A) 348.2 1.5 ##STR00046##
1-(1-methyl-6-oxo-1,6- dihydropyridazin-3-yl)piperidin- 4-yl
4-cyclobutylpiperazine-1- carboxylate 1.44(A) 376.3 1.6
##STR00047## 1-(1-ethyl-6-oxo-1,6- dihydropyridazin-3-yl)piperidin-
4-yl 4-isopropylpiperazine-1- carboxylate 0.87(A) 378.2 2.1
##STR00048## 1-(1-methyl-2-oxo-1,2-
dihydropyridin-4-yl)piperidin-4-yl 4-isopropylpiperazine-1-
carboxylate 1.31(B) 363.3 2.2 ##STR00049##
1-(2-oxo-1,2-dihydropyridin-4- yl)piperidin-4-yl 4-
cyclobutylpiperazine-1- carboxylate 1.31(B) 361.2 2.3 ##STR00050##
1-(2-oxo-1,2-dihydropyridin-4- yl)piperidin-4-yl 4-
isopropylpiperazine-1- carboxylate 1.26(B) 349.2 3.1 ##STR00051##
1-(6-oxo-1,6-dihydropyridin-3- yl)piperidin-4-yl 4-
isopropylpiperazine-1- carboxylate 1.37(C) 349.2
Biological Testing
1.1 In-vitro Testing
A) Potency Assessment
[0232] The potency of compounds of the invention as H3 receptor
antagonists can be assessed by measuring the blockade of
(R)-alpha-methylhistamine-mediated cAMP production utilizing a
LANCE Ultra cAMP kit (PE #TRF0263) in CHO cells expressing human H3
receptors (GenBank: BC096840; Strausberg R L et al, Proc. Natl.
Acad. Sci. U.S.A. 99(26), 16899-16903; 2002).
Protocol:
[0233] 1. Preparation of the stimulation buffer (30 ml): 29.4 ml
HBSS (GIBCO #14025), 150 .mu.l 1 M HEPES (GIBCO #15630), 30 .mu.l
500 mM IBMX (CALBIOCHEM #410957) and 400 .mu.l 7.5 BSA (GIBCO
#10438-026). 2. Preparation of assay plate: Different
concentrations of the compounds of the invention (0.01-1000 nM), H3
positive controls and cAMP calibration standards; 3 mM Forskolin
(CALBIOCHEM #344270); 5 .mu.M (R)-alpha-methylhistamine (H3
receptor agonist); 1% DMSO (SIGMA #D2650); total volume: 95 nl. 3.
Preparation of the cell solution: Collect cells with stimulation
buffer, final density: 100,000 cells/ml. 4. Reaction: (a) transfer
10 .mu.l of cell solution to assay plate, (b) centrifuge at 600 rpm
for 3 min and incubate 50 min at room temperature, (c) add 5 .mu.L
4.times. Eu-cAMP tracer solution (60 .mu.l Eu-cAMP tracer stock
solution+2.94 ml cAMP detection buffer) and 5 .mu.L 4.times.
ULight.TM.-anti-cAMP solution (20 .mu.l Eu-cAMP tracer stock
solution+2.98 ml cAMP detection buffer) to assay plate. 5. Reading
plate on EnVision: flash energy: 100%; excitation filter: 111 UV2
320; emission filter: 203 (Eu 615) and 205 (APC 665); number of
laser flashes: 20; window: 100 .mu.s; laser mirror module: 445 or
446; laser cycle: 16,600 .mu.s. 6. Data analysis by GraphPad Prism:
log (compound concentration) vs. response; variable slope.
B) Affinity Assessment
[0234] The affinity of compounds of the invention to the H3
receptor can be assessed by measuring displacement of binding of
the radioligand [3H]--N-.alpha.-Methylhistamine (PerkinElmer, #
NET1027250UC) to membranes containing human H3 receptors
(PerkinElmer, # ES-392-M400UA; GenBank: NM_007232.2; Hill S J et
al, International Union of Pharmacology XIII. Classification of
histamine receptors, Pharmacol Rev, 49(3), 253-278, 1997).
Protocol:
[0235] 1. Preparation of binding assay buffer (500 ml): 25 ml 1 M
Tris-HCl pH 7.5 (Invitrogen, #15567-027), 2.5 ml 1 M MgCl2 (Sigma,
# M1028-100ML), 472.5 ml ddH2O. 2. Compound serial dilution:
Dilution was performed by BioTek Precision on compound dilution
plate. Compound concentrations start at 5 or 10 .mu.M, 10 point
dose titrations with 3- or 5-fold serial dilutions. 3. Preparation
of 2.times. membrane solution (25 ml): 1.25 ml human Histamine H3
receptor stock, 23.75 ml assay buffer. 4. Preparation of 2.times.
solution of [3H]--N-.alpha.-methylhistamine (25 ml): 4.27 .mu.l
[3H]--N-.alpha.-methylhistamine stock, 25 ml assay buffer. 5.
Assemble binding reaction: (a) transfer 1 .mu.l of compound
solution, 1 .mu.l 100% DMSO and 1 .mu.l 1 M
(R)(-)-.alpha.-Methylhistamine (Sigma, # H128) to the reaction
plate at room temperature, (b) transfer 50 .mu.l of 2.times.
protein solution to reaction plate, (c) transfer 49 .mu.l of
2.times. radioligand solution to reaction plate (Corning.RTM. 96
well EIA/RIA plate; Sigma, # CLS3797). 6. Cover the reaction plate
with a TopSeal.TM.-A film (Perkin Elmer, #6005185) and incubate at
28.degree. C. for 120 min. Equilibrate Zeba Spin Desalting Plates
(Thermo Scientific, #89808) to room temperature for 120 min. 7.
Remove the sealing material from the bottom of the filtration
plate. Place the plate on a wash plate. Centrifuge at 1000 g for 2
min to remove the storage buffer at room temperature. 8. Transfer
70 .mu.l binding reaction from reaction plate into filtration
plates. Place the filtration plates on top of collection plate.
Centrifuge the plate assembly at 1000 g for 2 min to collect the
protein with bound radioligand. Add 200 .mu.l of Microscint-40
(PerkinElmer, #6013641-1L) to each well of the collection plate.
Cover the plates with TopSeal.TM.-A film. 9. Read the plates on
Wallac Microbeta Trilux 2450, Instrument settings: counting mode:
CPM, counting time: 2 min. 10. Data analysis: GraphPad Prism:
log(compound concentration) vs. response; variable slope. The Ki is
calculated based on Chang and Prusoff:
Ki=1C50/{1+([radioligand]/Kd)}
[0236] Table 2 represents Ki values from above described
potency/affinity assessments of compounds of the invention against
human H3 receptors.
TABLE-US-00002 TABLE 2 Potency Affinity Ki Ki Example (nM) (nM) 1.1
1.3 26 1.2 2.4 31 1.3 1.2 10 1.4 2.3 25 1.5 1.1 25 1.6 2.9 44 2.1
3.1 20 2.2 0.5 25 2.3 0.9 12 3.1 1.6 1.2
1.2 In-vivo Testing
A) Effects on Brain Tele-Methylhistamine Levels
[0237] Compounds of the invention were dissolved in 20%
2-hydroxyl-beta-cyclodextran (HBC) and then sonicated briefly until
there is little or no suspension in the solution. Animals (male
Sprague-Dawley rats at the age of 8 weeks) were orally dosed with
test compounds 1 hour or other longer time points before they were
sacrificed using CO.sub.2.
Blood Sample Collection:
[0238] A cardiac puncture was performed to collect blood sample
from the cardiac cavity. The collected blood was immediately mixed
with EDTA-K2 20 .mu.l/ml to avoid blood clotting. The blood samples
in tubes were then centrifuged (15 mim, 6000 rpm) and the plasma
transferred to new tubes and then temporarily kept in dry ice until
they were stored in a -70.degree. C. freezer.
[0239] CSF collection: CSF samples were taken from the foramen
magnum of the animal (using a #0.5 intravenous needle), and the CSF
sample were kept in dry ice.
Brain Tissue Collection:
[0240] The rat brain were taken out of the skull and rinsed with
ice-cold saline first. The frontal cortex was separated from the
rest of the brain on top of a petri dish with ice underneath. The
wet weight of the frontal cortex was weighed and recorded
immediately. The frontal cortex sample was then kept in dry ice
until they are transferred to a -70.degree. C. freezer.
Bioanalytical Methods for Tele-Methyl Histamine and Compounds:
[0241] Instrument: Agilent 6410, triple quadrupole mass
spectrometer
[0242] Matrix: rat plasma, frontal cortex homogenate and
cerebrospinal fluid (CSF)
[0243] Analyte: H3 compounds.
[0244] Internal standard: Dexamethasone
HPLC Conditions Mobile Phase A: H2O-0.1% NH3.H2O:
[0245] Mobile phase B: MeOH-0.1% NH3.H2O
[0246] Column: Ultimate XB-C18 (2.1.times.50 mm, 5 .mu.m)
[0247] Flow rate: 0.45 mL/min, temperature: 40.degree. C.
MS conditions:
[0248] ESI: positive ion
[0249] MRM detection
[0250] Dexamethasone: [M+H]+m/z 393.3.fwdarw.373.2; CE:4;
Fragmentor:110
Sample Preparation:
Frontal Cortex:
[0251] the brain sample was homogenized for 2 min with 3 volumes
(v/w) of homogenizing solution (EtOH:PBS=85:15), and then
centrifuged at 12,000 rpm for 5 min. The 30 .mu.L supernatant of
brain homogenate sample was added with 30 .mu.L of the internal
standard (Dexamethasone, 300 ng/mL) and then followed by 150 .mu.L
ACN for protein precipitation. The mixture was vortexed for 2 min
and centrifuged at 12000 rpm for 5 min. The 5 .mu.L supernatant was
injected onto LC-MS/MS for analysis.
Plasma and CSF:
[0252] an aliquot of 30 .mu.L sample was added with 30 .mu.L of the
internal standard (300 ng/mL Dexamethasone) and then followed by
150 .mu.L ACN for protein precipitation. The mixture was vortexed
for 2 min and centrifuged at 12000 rpm for 5 min. The 5 .mu.L
supernatant was injected onto LC-MS/MS for analysis.
[0253] Table 3 represents data from measurements of the
tele-methylhistamine level in brain.
TABLE-US-00003 TABLE 3 % change in telemethylhistamine brain levels
Example for 10 mg/kg @ 1 h 1.1 72 1.2 138 1.3 115
B) Effects on Wakefulness
[0254] Animals: Male Sprague-Dawly rats (280-320 g) were were
housed individually under an ambient temperature of
22.+-.0.5.degree. C. with a relative humidity of 60.+-.2% and an
automatically controlled 12-h light/12-h dark cycle (light on at
07:00, illumination intensity=100 lux). The animals had free access
to food and water.
[0255] EEG recording set up, Polygraphic Recordings and Vigilance
State Analysis: Under pentobarbital anesthesia (50 mg/kg, i.p.),
rats were chronically implanted with EEG and electromyogram (EMG)
electrodes for polysomnographic recordings (Huang et al, J
Neurosci, 23, 5975-5983, 2003). Two stainless steel screws (1 mm in
diameter) EEG electrodes (the first screw: anteroposterior (AP), +2
mm; left-right (LR), -2 mm; and the second: AP, -2 mm; LR, -2 mm,
AP from bregma, LR from lambda) and a reference electrode (opposite
to EEG screw side, AP, +3 mm; LR, 3 mm) were surgically implanted
and 3 stainless steel screws for anchorage to the skull. Two
insulated stainless steel, Teflon-coated wires were bilaterally
placed into both trapezius muscles and served as EMG electrodes for
rats. All electrodes were attached to a micro connector and fixed
to the skull with dental cement.
[0256] The EEG and EMG recordings were carried out by means of a
slip ring designed so that behavioral movement of the rat would not
be restricted. After an 8-day recovery period, the rats were housed
individually in transparent barrels and habituated to the recording
cable for 3-4 days before polygraphic recording.
[0257] For the study of spontaneous sleep-wakefulness cycles, each
animal was recorded for 24 h beginning at 19:00 P.M., the offset of
the light period. The animals then entered the pharmacological
phase of the study, in which sleep-wakefulness parameters were
recorded for 72 h. The data collected during the first 24 h also
served as baseline comparison data for the second experimental
day.
[0258] Cortical EEG and EMG signals were amplified, filtered (EEG,
0.5-30 Hz; EMG, 20-200 Hz), digitized at a sampling rate of 128 Hz,
and recorded by using SLEEPSIGN (Kissei Comtec, Nagano, Japan).
When complete, polygraphic recordings were automatically scored
offline by 4-sec epochs as wake, REM, and NREM sleep by SleepSign
according to standard criteria (Huang et al, Nat Neurosci, 8,
858-859, 2005). As a final step, defined sleep-wake stages were
examined visually and corrected, if necessary. EEG power density
curve was plotted for each stage during 4 h after drug
administration. The power of each 0.25 Hz bin was averaged across
the sleep or wake stage and normalized as a group by calculating
the percentage of each bin from the total power (0.25-25 Hz).
[0259] Pharmacological Treatments: Tested compounds, caffeine
(positive reference compound) or compounds of the invention were
prepared in 20% 2-hydroxyl-beta-cyclodextran (HBC). On the
vehicle-treated day, all animals were administered with vehicle at
9:00 A.M. On the drug-treated day, the test compound, caffeine, or
vehicle was given at 9:00 A.M. Thereafter, continuous recording was
kept to the 3rd day. The volume was injected oral, or
intraperitoneally at 2 ml/kg. Separate groups of rats were used for
each dose (n=8 rats per group).
[0260] Time-course changes in the amounts of sleep-wake, sleep/wake
stage transition number, as well as number and duration of
sleep/wake bouts in light/dark phases, were analyzed by the paired
t test, with each animal serving as its own control.
[0261] Table 4 represents data from measurements of percent
increase in wakefulness in rats. Date is given for first 4 hours
after oral compound administration.
TABLE-US-00004 TABLE 4 % increase in wakefulness Example at 10 mg
1.1 42.1 1.2 48.8 1.3 19.1 * p < 0.5, ** p < 0.01 (comparison
with vehicle group)
[0262] In one embodiment, the invention provides a method of
inhibiting H3 receptors in a subject, wherein the method comprises
administering to the subject a therapeutically effective amount of
a compound of formula I or a pharmaceutically acceptable salt
thereof.
[0263] In a further embodiment, the invention provides a method of
treating a disorder or a disease in a subject mediated by H3
receptors, wherein the method comprises administering to the
subject a therapeutically effective amount of a compound of formula
I or a pharmaceutically acceptable salt thereof. Preferably said
disorder or said disease is selected from narcolepsy; fatigue
associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; and
Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0264] In yet a further embodiment, the invention provides the use
of a compound of formula I or a pharmaceutically acceptable salt
thereof, for the treatment of a disorder or disease in a subject
mediated by H3 receptors.
[0265] In yet a further embodiment, the invention provides the use
of a compound of formula I or a pharmaceutically acceptable salt
thereof, for the treatment of a disorder or disease in a subject
characterized by an abnormal activity of H3 receptors. Preferably
said disorder or said disease is selected from narcolepsy; fatigue
associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; and
Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0266] In yet a further embodiment, the invention provides the use
of a compound of formula I or a pharmaceutically acceptable salt
thereof, for the treatment of a disorder or disease in a subject
associated with irregularities of H3 receptor-modulated signal
transmission. Preferably said disorder or said disease is selected
from narcolepsy; fatigue associated with multiple sclerosis;
fatigue associated with Parkinson's disease; cognitive impairment
associated with schizophrenia; cognitive impairment associated with
Alzheimer's disease; mild cognitive impairment; Tourette syndrome;
and Attention-deficit hyperactivity disorder; very especially
narcolepsy.
II. SOLID FORMS OF CARBAMATE DERIVATIVES
[0267] The present invention also relates to solid forms of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate and to pharmaceutical
compositions comprising them, and to their use as medicaments.
[0268] The compound
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate of the formula IA
##STR00052##
is described hereinbefore.
[0269] Selection criteria for solid forms depend on the planned
indications and route(s) of administration. For a CNS-indication,
such as narcolepsy, with an envisaged oral route of administration
it is important to e.g. achieve a good absorption/oral
bioavailability. Especially suitable solid forms are crystalline
forms having a low hygroscopy, a high aqueous solubility, a high
melting point and do not exist in multiple forms (e.g. polymorphs,
solvates and/or hydrates). Further relevant parameters are safety
aspects (e.g. low toxicity), stability in bulk, compatibility with
excipients, pH of aqueous solution, good morphology and easy
handling.
[0270] The invention provides the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form. The invention
further provides a salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form, wherein said
salt is the citrate, hydrochloride, fumarate, adipate, maleate or
sebacate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. Unless specified otherwise,
said free form or said salt together will be referred to
hereinafter as "SOLID FORM OF THE INVENTION".
[0271] As used herein "solid form" may include hydrates and
solvates.
[0272] As used herein "crystalline form" referes to a solid form of
a molecule, atom and/or ion, in which its constituent atoms,
molecules and/or ions are arranged in an orderly repeating pattern
extending in all three spatial dimensions.
[0273] As used herein "polymorph" refers to crystalline forms
having the same chemical composition but different spatial
arrangements of the molecules, atoms and/or ions forming the
crystal.
[0274] As used herein "amorphous form" refers to a solid form of a
molecule, atom and/or ion that is not crystalline. An amorphous
solid does not display a definitive X-ray diffraction pattern.
[0275] As used herein "solvate" refers to a form, e.g. a
crystalline form, of a molecule, atom and/or ions that further
comprises molecules of a solvent or solvents incorporated into the
solid structure, e.g. crystalline lattice structure. The solvent
molecules in the solvate may be present in a regular arrangement
and/or a non-ordered arrangement. The solvate may comprise either a
stoichiometic or nonstochiometric amount of the solvent molecules.
For example, a solvate with a nonstochiometric amount of solvent
molecules may result from partial loss of solvent form the solvate.
Solvates may occur as dimers or oligomers comprising more than one
molecule of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate within a crystalline lattice
structure.
[0276] As used herein "substantially pure", when used in reference
to a solid form, means a compound, e.g. a salt (such as the citrate
of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate), having a purity greater than
90 weight %, including greater than 90, 91, 92, 93, 94, 95, 96, 97,
98, and 99 weight %, and also including equal to about 100 weight %
of the compound, e.g. of the citrate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate, based on the weight of the
solid form. The remaining material in the solid form may comprise
e.g. reaction impurities and/or processing impurities arising from
its preparation and/or--if applicable--other form(s) of the
compound. For example, a crystalline form of the citrate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate may be deemed substantially
pure in that it has a purity greater than 90 weight %, as measured
by means that are at this time known and generally accepted in the
art, where the remaining less than 10 weight % of material
comprises reaction impurities and/or processing impurities.
[0277] As used herein "mono-" in connection with acids refers to a
base to acid ratio of about 1:1.
[0278] As used herein "sesqui-" in connection with acids refers to
a base to acid ratio of about 1:1.5.
[0279] As used herein "di-" in connection with acids refers to a
base to acid ratio of about 1:2.
[0280] The term "substantially the same" with reference to X-ray
diffraction peak positions means that typical peak position and
intensity variability are taken into account. For example, one
skilled in the art will appreciate that the peak positions (2e)
will show some inter-apparatus variability, typically as much as
0.2.degree.. Further, one skilled in the art will appreciate that
peak intensities will show inter-apparatus variability as well as
variability due to degree of crystallinity, preferred orientation,
prepared sample surface, and other factors known to those skilled
in the art, and should be taken as qualitative measure only.
1. Free Form
[0281] In one embodiment, the SOLID FORM OF THE INVENTION is the
free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate, e.g. in crystalline form.
1.1. First Embodiment of Free Form
[0282] A free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form A of
the free form) may be produced from cooling crystallization of a
supersaturated solution of the compound in ethyl acetate at
concentrations of about 100 mg/ml. The clear point (temperature at
which the compound will dissolve) is about 35.degree. C. The cloud
point (temperature at which the compound will crystallize) is about
4.degree. C. The XRPD pattern of a sample prepared according to
such a method (see also Example II.1.1) is shown in FIG. 1A.
Measurements were performed at a temperature of about 22.degree. C.
and an x-ray wavelength, .lamda., of 1.5418 .ANG. (CuK.alpha.
.lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00005 [0283] 2 theta Intensity No. (deg .degree.) (cts) 1
4.9 5305 2 9.7 2288 3 14.5 726 4 14.6 564 5 15.4 9230 6 16.0 3079 7
16.9 3327 8 17.3 1215 9 18.1 1995 10 19.5 2862 11 20.5 13826 12
20.8 8027 13 21.3 2578 14 21.4 2373 15 22.9 535 16 24.4 7248 17
24.8 918 18 26.0 400 19 26.8 799 20 28.8 460 21 29.4 1197 22 31.0
699 23 35.5 355 24 39.5 352
[0284] In one embodiment, Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 4.9, 15.4, 16.9, 20.5,
20.8 and 24.4, .+-.0.2, respectively.
[0285] In one embodiment, Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 1A.
[0286] Form A of the free from shows good solubility in aqueous
media across a pH range from about 1-8. Its melting point was
determined by heating at 10.degree. C./minute to be about
123.degree. C.
1.2. Second Embodiment of Free Form
[0287] A free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form B of
the free form) was found as described in the Examples section (see
Example II.1.2). The associated XRPD pattern is shown in FIG.
1B.
Summary of XRPD Pattern:
TABLE-US-00006 [0288] 2 theta Intensity No. (deg .degree.) (cts) 1
9.4 386 2 11.3 2380 3 13.6 348 4 15.0 2422 5 16.0 481 6 16.7 2577 7
17.4 1391 8 18.3 738 9 18.6 802 10 19.4 7589 11 20.8 1401 12 21.7
454 13 22.7 2907 14 23.2 7040 15 24.0 306 16 24.6 1591 17 27.7
10625 18 27.8 5756 19 28.1 712 20 28.7 1879 21 29.5 674 22 29.9
1086 23 31.6 637 24 32.5 1248 25 32.7 910 26 33.5 724 27 33.6 954
28 34.3 623 29 35.1 359 30 35.6 358 31 36.1 992 32 37.0 457 33 37.7
333 34 39.2 330
[0289] In one embodiment, Form B of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 9.4, 11.3, 13.6, 15.0,
16.0, 16.7, 17.4, 18.3, 18.6, 19.4, 20.8, 21.7, 22.7, 23.2, 24.0,
24.6, 27.7, 27.8, 28.1, 28.7, 29.5, 29.9, 31.6, 32.5, 32.7, 33.5,
33.6, 34.3, 35.1, 35.6, 36.1, 37.0, 37.7, and 39.2, .+-.0.2,
respectively.
[0290] In one embodiment, Form B of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 9.4, 19.4, 22.7, 23.2,
27.7 and 27.8, .+-.0.2, respectively.
[0291] In one embodiment, Form B of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 1B.
[0292] Form B of the free from shows good solubility in aqueous
media. Its melting point was determined by heating at 10.degree.
C./minute to be about 124.degree. C. (onset).
Salts
2. Citrate Salt
[0293] In one embodiment, the SOLID FORM OF THE INVENTION is the
citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate, e.g. in crystalline form.
2.1. First Embodiment of Citrate Salt
[0294] A citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form A of
the citrate salt) may be produced from acetone/diethylether when
two equivalents citric acid are used.
[0295] It shows good solubility in aqueous media. Its melting point
was determined by heating at 10.degree. C./minute to be about
141.2.degree. C.
[0296] The X-ray powder diffraction (XRPD) pattern of a sample
prepared according to this method (see also Example II.2.1) is
shown in FIG. 2A. Measurements were performed at a temperature of
about 22.degree. C. and an x-ray wavelength, .lamda., of 1.5418
.ANG. (CuK.alpha. .lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00007 [0297] 2 theta No. (deg .degree.) Intensity 1 19.4
130 2 24.0 130 3 14.0 128 4 16.6 128 5 17.5 128 6 17.3 122 7 12.0
118 8 20.8 110 9 25.6 108 10 16.1 103 11 22.5 103 12 18.2 99 13
20.1 97 14 10.2 93 15 31.3 82 16 8.4 60 17 5.5 57
[0298] In one embodiment, Form A of the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 14.0, 16.6, 17.3, 17.5,
19.4 and 24.0.+-.0.2, respectively.
[0299] In one embodiment, Form A of the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 2A.
[0300] Analysis of the proton-NMR spectrum for the salt of Example
II.2.1 (see FIG. 2B) demonstrated a base/acid ratio of about
1:1.5.
[0301] In one embodiment, the SOLID FORM OF THE INVENTION is the
sesqui-citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate.
[0302] In one embodiment, the SOLID FORM OF THE INVENTION is the
sesqui-citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
2.2. Second Embodiment of Citrate Salt
[0303] A citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form B of
the citrate salt) may be produced from acetone when one equivalent
citric acid is used.
[0304] It shows good solubility in aqueous media. Its melting point
was determined by heating at 10.degree. C./minute to be about
172.degree. C.
[0305] The X-ray powder diffraction (XRPD) pattern of a sample
prepared according to this method (see also Example II.2.2) is
shown in FIG. 2C. The sample contained about 1.5% of residual
acetone. Measurements were performed at a temperature of about
22.degree. C. and an x-ray wavelength, .lamda., of 1.5418 .ANG.
(CuK.alpha. .lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00008 [0306] 2 theta Intensity No. (deg .degree.) (cts) 1
3.2 406 2 5.8 54 3 9.3 1460 4 10.8 321 5 12.0 1561 6 12.7 134 7
14.1 110 8 15.1 204 9 16.3 811 10 16.4 772 11 17.3 1164 12 18.3 437
13 18.6 406 14 19.3 425 15 20.7 469 16 22.0 97 17 23.3 271 18 23.9
308 19 25.9 138 20 26.7 98 21 27.9 38 22 31.0 27 23 31.7 35 24 32.5
50 25 34.9 60 26 37.2 65
[0307] In one embodiment, Form B of the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 3.2, 9.3, 10.8, 12.0,
15.1, 16.3, 16.4, 17.3, 18.3, 18.6, 19.3, 20.7, 23.3, and 23.9,
.+-.0.2, respectively.
[0308] In one embodiment, Form B of the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 2C.
3. Hydrochloride Salt
[0309] In one embodiment, the SOLID FORM OF THE INVENTION is the
hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate, e.g. in crystalline form.
4.1. First Embodiment of Hydrochloride Salt
[0310] A hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form A of
hydrochloride salt) may be produced from acetone when one
equivalent hydrochloric acid is used.
[0311] It shows good solubility in aqueous media. Its melting point
was determined by heating at 10.degree. C./minute to be
249.8.degree. C. (onset) with subsequent decomposition.
[0312] The XRPD pattern pattern of a sample prepared according to
this method (see also Example II.3.1) is shown in FIG. 3A.
Measurements were performed at a temperature of about 22.degree. C.
and an x-ray wavelength, .lamda., of 1.5418 .ANG. (CuK.alpha.
.lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00009 [0313] 2 theta No. (deg .degree.) Intensity 1 16.4
287 2 24.8 215 3 27.5 153 4 20.2 119 5 29.7 103 6 17.2 96 7 27.0 94
8 22.0 91 9 19.0 82 10 23.9 81 11 10.9 77 12 36.4 68 13 39.0 66 14
14.0 59 15 31.2 56 16 43.6 38 17 40.5 37
[0314] In one embodiment, Form A of the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 16.4, 17.2, 20.2, 24.2,
27.5 and 29.7.+-.0.2, respectively.
[0315] In one embodiment, Form A of the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 3A.
4.2. Second Embodiment of Hydrochloride Salt
[0316] An anhydrous hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form B of
hydrochloride salt) may be produced from acetone when two
equivalents hydrochloric acid are used.
[0317] It shows good solubility in aqueous media. Its melting
point, for a sample stored at 40.degree. C. and 75% relative
humidity for 7 days, was determined by heating at 10.degree.
C./minute to be about 250.degree. C. (onset).
[0318] The X-ray powder diffraction (XRPD) pattern of a sample
prepared according to this method (see also Example II.3.2) is
shown in FIG. 3B. Measurements were performed at a temperature of
about 22.degree. C. and an x-ray wavelength, .lamda., of 1.5418
.ANG. (CuK.alpha. .lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00010 [0319] 2 theta Intensity No. (deg .degree.) (cts) 1
5.7 98 2 9.1 76 3 10.0 603 4 10.7 521 5 11.9 463 6 13.3 418 7 13.7
163 8 15.4 191 9 15.9 970 10 16.5 225 11 16.8 127 12 17.1 135 13
18.3 494 14 18.7 443 15 19.5 439 16 20.0 80 17 20.7 82 18 22.9 36
19 23.6 323 20 24.2 136 21 25.0 595 22 25.4 137 23 26.9 1100 24
27.0 966 25 27.7 296 26 29.4 198 27 30.1 67 28 31.9 51 29 32.7 63
30 34.2 20 31 35.9 30 32 38.1 22
[0320] In one embodiment, Form B of the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 5.7, 9.1, 10.0, 10.7,
11.9, 13.3, 13.7, 15.4, 15.9, 16.5, 16.8, 17.1, 18.3, 18.7, 19.5,
20.0, 20.7, 23.6, 24.2, 25.0, 25.4, 26.9, 27.0, 27.7, 29.4, 30.1,
31.9, and 32.7, .+-.0.2, respectively.
[0321] In one embodiment, Form B of the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 3B.
4. Fumarate Salt
[0322] In one embodiment, the SOLID FORM OF THE INVENTION is the
fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate, e.g. in crystalline form.
3.1. First Embodiment of Fumarate Salt
[0323] An anhydrous fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form A of
fumarate salt) may be produced from methanol/acetone as described
in Example 4.1 when one equivalent fumaric acid is used.
[0324] It shows good solubility in aqueous media. Its melting point
was determined by heating at 10.degree. C./minute to be about
156.degree. C.
[0325] The X-ray powder diffraction (XRPD) pattern of a sample
prepared according to this method (see also Example II.4.1) is
shown in FIG. 4A. Measurements were performed at a temperature of
about 22.degree. C. and an x-ray wavelength, .lamda., of 1.5418
.ANG. (CuK.alpha. .lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00011 [0326] 2 theta Intensity No. (deg .degree.) (cts) 1
6.5 662 2 10.1 1209 3 10.7 813 4 12.4 156 5 13.0 3669 6 13.9 661 7
16.0 90 8 16.7 1428 9 16.8 1725 10 17.2 2712 11 17.7 290 12 18.8
209 13 20.2 1475 14 20.5 631 15 21.6 1518 16 21.9 1748 17 22.1 1795
18 23.1 237 19 23.4 100 20 25.0 1464 21 25.1 1002 22 25.4 603 23
26.4 114 24 27.5 297 25 28.0 790 26 28.8 293 27 29.9 255 28 32.8
149 29 33.2 174 30 33.7 80 31 38.3 73
[0327] In one embodiment, Form A of the fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 6.5, 10.1, 10.7, 12.4,
13.0, 13.9, 16.7, 16.8, 17.2, 17.7, 18.8, 20.2, 20.5, 21.6, 21.9,
22.1, 23.1, 23.4, 25.0, 25.1, 25.4, 26.4, 27.5, 28.0, 28.8, 29.9,
32.8, and 33.2, .+-.0.2, respectively.
[0328] In one embodiment, Form A of the fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 4A.
3.2. Second Embodiment of Fumarate Salt
[0329] An anhydrous fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form (Form B of
fumarate salt) may be produced from methanol/acetone as described
in Example 4.2 when two equivalents fumaric acid are used.
[0330] It shows good solubility in aqueous media. Its melting point
was determined by heating at 10.degree. C./minute to be about
155.degree. C.
[0331] The X-ray powder diffraction (XRPD) pattern of a sample
prepared according to this method (see also Example II.4.2) is
shown in FIG. 4B. Measurements were performed at a temperature of
about 22.degree. C. and an x-ray wavelength, .lamda., of 1.5418
.ANG. (CuK.alpha. .lamda.=1.5418 .ANG.).
Summary of XRPD Pattern:
TABLE-US-00012 [0332] 2 theta Intensity No. (deg .degree.) (cts) 1
6.4 549 2 7.8 112 3 8.7 462 4 10.6 232 5 11.3 215 6 11.8 742 7 12.9
523 8 13.1 178 9 13.8 1953 10 14.0 1727 11 15.2 176 12 15.7 1780 13
16.2 736 14 16.6 1901 15 16.9 335 16 18.3 110 17 18.7 954 18 18.8
689 19 19.1 2404 20 19.3 562 21 19.7 318 22 20.1 146 23 20.5 323 24
21.0 1741 25 21.4 840 26 21.9 2681 27 22.8 669 28 23.8 364 29 24.0
1027 30 24.4 317 31 24.7 524 32 25.2 935 33 25.6 448 34 26.0 566 35
26.1 699 36 27.8 528 37 28.3 123 38 29.1 220 39 29.5 353 40 30.6
201 41 31.4 256 42 31.7 142 43 32.1 318 44 32.7 308 45 34.7 98 46
35.3 194 47 37.4 154 48 38.2 168
[0333] In one embodiment, Form B of the fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern with at least four, more
preferably five, most preferably all of the following peaks at an
angle of refraction 2 theta (2.theta.) of 6.4, 8.7, 10.6, 11.3,
11.8, 12.9, 13.8, 14.0, 15.7, 16.2, 16.6, 16.9, 18.7, 18.8, 19.1,
19.3, 19.7, 20.5, 21.0, 21.4, 21.9, 22.8, 23.8, 24.0, 24.4, 24.7,
25.2, 25.6, 26.0, 26.1, 27.8, 29.1, 29.5, 30.6, 31.4, 32.1, 32.7,
and 35.3, .+-.0.2, respectively.
[0334] In one embodiment, Form B of the fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 4B.
Preparation Methods for Crystalline Forms
[0335] Crystalline forms may be prepared by a variety of methods,
including for example, crystallization or recrystallization from a
suitable solvent, sublimation, growth from a melt, solid state
transformation from another phase, crystallization from a
supercritical fluid, and jet spraying. Techniques for
crystallization or recrystallization of crystalline forms from a
solvent mixture include, for example, evaporation of the solvent,
decreasing the temperature of the solvent mixture, crystal seeding
a supersaturated solvent mixture of the molecule and/or salt,
freeze drying the solvent mixture, and addition of antisolvents
(countersolvents) to the solvent mixture. High throughput
crystallization techniques may be employed to prepare crystalline
forms including polymorphs.
[0336] Crystals of drugs, including polymorphs, methods of
preparation, and characterization of drug crystals are discussed in
Solid-State Chemistry of Drugs, S. R. Byrn, R. R. Pfeiffer, and J.
G. Stowell, 2.sup.nd Edition, SSCI, West Lafayette, Ind.
(1999).
[0337] For crystallization techniques that employ solvent, the
choice of solvent or solvents is typically dependent upon one or
more factors, such as solubility of the compound, crystallization
technique, and vapor pressure of the solvent. Combinations of
solvents may be employed, for example, the compound may be
solubilized into a first solvent to afford a solution, followed by
the addition of an antisolvent to decrease the solubility of the
compound in the solution and to afford the formation of crystals.
An antisolvent is a solvent in which the compound has low
solubility.
[0338] In one method to prepare crystals, a compound is suspended
and/or stirred in a suitable solvent to afford a slurry, which may
be heated to promote dissolution. The term "slurry", as used
herein, means a saturated solution of the compound, which may also
contain an additional amount of the compound to afford a
heterogeneous mixture of the compound and a solvent at a given
temperature.
[0339] Seed crystals may be added to any crystallization mixture to
promote crystallization (see "Programmed Cooling of Batch
Crystallizers," J. W. Mullin and J. Nyvlt, Chemical Engineering
Science, 1971, 26, 369-377). In general, seed crystals of small
size are used. Seed crystals of small size may be generated by
sieving, milling, or micronizing of large crystals, or by
micro-crystallization of solutions. Care should be taken that
milling or micronizing of crystals does not result in any change in
crystallinity form the desired crystal form (i.e., change to
amorphous or to another polymorph).
[0340] A cooled crystallization mixture may be filtered under
vacuum, and the isolated solids may be washed with a suitable
solvent, such as cold recrystallization solvent, and dried under a
nitrogen purge to afford the desired crystalline form. The isolated
solids may be analyzed by a suitable spectroscopic or analytical
technique, such as solid state nuclear magnetic resonance,
differential scanning calorimetry, x-ray powder diffraction, or the
like, to assure formation of the preferred crystalline form of the
product. The resulting crystalline form is typically produced in an
amount of greater than about 70 weight % isolated yield, preferably
greater than 90 weight % isolated yield, based on the weight of the
compound originally employed in the crystallization procedure. The
product may be delumped by sieving or forced sieving, if
necessary.
[0341] Crystalline forms may be prepared directly from the reaction
medium of the final process for preparing
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate or a SOLID FORM OF THE
INVENTION. This may be achieved, for example, by employing in the
final process step a solvent or a mixture of solvents from which
the SOLID FORM OF THE INVENTION may be crystallized. Alternatively,
crystalline forms may be obtained by distillation or solvent
addition techniques. Suitable solvents for this purpose include,
for example, nonpolar solvents and polar solvents, including protic
polar solvents such as alcohols, and aprotic polar solvents such as
ketones.
[0342] The presence of more than one polymorph in a sample may be
determined by techniques such as powder x-ray diffraction (PXRD) or
solid state nuclear magnetic resonance spectroscopy. For example,
the presence of extra peaks in the comparison of an experimentally
measured PXRD pattern with a simulated PXRD pattern may indicate
more than one polymorph in the sample. The simulated PXRD may be
calculated from single crystal x-ray data; see Smith, D. K., "A
FORTRAN Program for Calculating X-Ray Powder Diffraction Patterns,"
Lawrence Radiation Laboratory, Livermore, Calif., UCRL-7196 (April
1963).
[0343] One embodiment of the invention is a method of preparing a
citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form comprising
the steps of
(a) preparing a solution of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate and citric acid in acetone,
wherein the
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate: citric acid ratio is about
1:2; (b) adding to the solution of step (a) an ether antisolvent,
e.g. diethyl ether, until an acetone:ether antisolvent volume ratio
from 1:1 to 1:5, e.g. about 1:3, is reached; and (e) isolate the
solids by filtration to obtain the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
[0344] One embodiment of the invention is a method of preparing a
hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form comprising
the steps of
(a) preparing a solution of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in acetone; (b) adding to the
solution of step (a) hydrochloric acid until a
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate:hydrochloric acid ratio of
about 1:1 is reached; and (e) isolate the solids by filtration to
obtain the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
Analysis of Solid Forms
[0345] The solid form of a SOLID FORM OF THE INVENTION may be
characterized using various techniques, the operation of which are
well known to those of ordinary skill in the art.
[0346] The forms may be characterized and distinguished using
single crystal x-ray diffraction, which is based on unit cell
measurements of a single crystal of the form at a fixed analytical
temperature. A detailed description of unit cells is provided in
Stout & Jensen, X-Ray Structure Determination: A Practical
Guide, Macmillan Co., New York (1968), Chapter 3. Alternatively,
the unique arrangement of atoms in spatial relation within the
crystalline lattice may be characterized according to the observed
fractional atomic coordinates. Another means of characterizing the
crystalline structure is by powder x-ray diffraction analysis in
which the diffraction profile is compared to a simulated profile
representing pure powder material, both run at the same analytical
temperature, and measurements for the subject form characterized as
a series of 20 values (usually four or more).
[0347] Other means of characterizing the form may be used, such as
solid state nuclear magnetic resonance (NMR), differential scanning
calorimetry, thermography and gross examination of the crystalline
or amorphous morphology. These parameters may also be used in
combination to characterize the subject form.
FURTHER ASPECTS
[0348] The invention also relates to a SOLID FORM OF THE INVENTION
(e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form) for use
as a medicament.
[0349] In another embodiment, the invention relates to a SOLID FORM
OF THE INVENTION (e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form) for the
treatment of a disorder or disease in a subject mediated by H3
receptors. Preferably said disorder or said disease is selected
from narcolepsy; fatigue associated with multiple sclerosis;
fatigue associated with Parkinson's disease; cognitive impairment
associated with schizophrenia; cognitive impairment associated with
Alzheimer's disease; mild cognitive impairment; Tourette syndrome;
and Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0350] In another embodiment, the invention also relates to the use
of a SOLID FORM OF THE INVENTION (e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form) for the
manufacture of a medicament for the prevention, treatment and/or
delay of progression of a disorder or disease in a subject mediated
by H3 receptors. Preferably said disorder or said disease is
selected from narcolepsy; fatigue associated with multiple
sclerosis; fatigue associated with Parkinson's disease; cognitive
impairment associated with schizophrenia; cognitive impairment
associated with Alzheimer's disease; mild cognitive impairment;
Tourette syndrome; and Attention-deficit hyperactivity disorder;
very especially narcolepsy.
[0351] In another embodiment, the invention also relates to the use
of a SOLID FORM OF THE INVENTION (e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form) for the
prevention, treatment and/or delay of progression of a disorder or
disease in a subject mediated by H3 receptors. Preferably said
disorder or said disease is selected from narcolepsy; fatigue
associated with multiple sclerosis; fatigue associated with
Parkinson's disease; cognitive impairment associated with
schizophrenia; cognitive impairment associated with Alzheimer's
disease; mild cognitive impairment; Tourette syndrome; and
Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0352] In another embodiment, the invention also relates to a
method for the prevention, treatment and/or delay of progression of
a disorder or disease in a subject mediated by H3 receptors, in a
subject in need of such treatment, which comprises administering to
such subject a therapeutically effective amount of a SOLID FORM OF
THE INVENTION (e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form).
Preferably said disorder or said disease is selected from
narcolepsy; fatigue associated with multiple sclerosis; fatigue
associated with Parkinson's disease; cognitive impairment
associated with schizophrenia; cognitive impairment associated with
Alzheimer's disease; mild cognitive impairment; Tourette syndrome;
and Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0353] In another embodiment, the invention relates to a method for
the prevention, treatment and/or delay of progression of a disorder
or disease in a subject mediated by H3 receptors, in a subject in
need thereof, which comprises (i) diagnosing said disorder or
disease in said subject and (ii) administering to said subject a
therapeutically effective amount of a SOLID FORM OF THE INVENTION
(e.g. Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form).
Preferably said disorder or said disease is selected from
narcolepsy; fatigue associated with multiple sclerosis; fatigue
associated with Parkinson's disease; cognitive impairment
associated with schizophrenia; cognitive impairment associated with
Alzheimer's disease; mild cognitive impairment; Tourette syndrome;
and Attention-deficit hyperactivity disorder; very especially
narcolepsy.
[0354] Amorphous forms/crystalline forms of SOLID FORMS OF THE
INVENTION are useful as intermediates for preparing crystalline
forms/other crystalline forms of SOLID FORMS OF THE INVENTION that
are useful in the treatment of the above diseases/conditions.
[0355] SOLID FORMS OF THE INVENTION may be used alone or in
combination, or formulated with one or more excipients and/or other
active pharmaceutical ingredients to provide formulations, as
described above, suitable for the treatment of the above
diseases/conditions.
[0356] The invention therefore also relates to a pharmaceutical
composition comprising a SOLID FORM OF THE INVENTION as active
ingredient and at least one pharmaceutically acceptable
carrier.
ABBREVATIONS
[0357] DSC Differential scanning calorimetry [0358] EGA evolved gas
analysis [0359] TGA thermo gravimetric analysis [0360] XRPD X-ray
powder diffraction
Example II.1.1
Preparation of free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0361] Free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was dissolved in ethyl acetate
at a concentration of 100 mg/ml under heating to its clear point of
35.degree. C. Cooling to its cloud point of 4.degree. C. yielded a
crystalline product. The product was analyzed by XRPD (see FIG.
1A).
Example II.1.2
Preparation of free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0362] In a vial, equipped with a magnetic stirring bar, 1
equivalent of each base listed in the table below was dissolved in
3 ml water. To this solution, 50 mg Form A of the free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate were added together with 2 ml
methanol. The mixture was stirred at room temperature until a clear
solution was obtained. Then, the stirring bar was removed and the
solution was left to evaporate at room temperature. After 17-24
days (see table below), a crystalline product was obtained. The
evaporation time and the amount of product obtained are listed
below:
TABLE-US-00013 Amount of Evaporation Base product time L-Lysine 19
mg 17 days N-Methyl Glucamine 26 mg 24 days L-Arginine 23 mg 18
days Sodium Hydroxide 5 mg 20 days Potassium Hydroxide 7 mg 24 days
Magnesium Hydroxide 8 mg 18 days Calcium Hydroxide 10 mg 24
days
[0363] Precipitates were collected and analyzed by XRPD. A typical
XRPD spectrum is depicted in FIG. 1B.
Example II.2.1
Preparation of citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0364] 2 g free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was dissolved in acetone (5
ml) under stirring at room temperature, and 2.04 g (2 equivalents)
of citric acid was also dissolved in acetone (5 ml) in the same
condition. In a 100 ml crystallizer, equipped with a magnetic
stirring bar and condenser, two solutions were added and stirred.
After half an hour, 30 ml diethyl ether was added into
crystallizer. The slurry was filtered, and the light yellow solid
was dried under vacuum at 40.degree. C. for 24 hours (yield:
82.28%). The product was analyzed by XRPD (see FIG. 2A) and
proton-NMR (see FIG. 2B). Analysis of the proton-NMR spectrum
demonstrated a base/acid ratio of about 1:1.5.
Example II.2.2
Preparation of citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0365] 25.58 mg of citric acid was dissolved in 3 ml acetone under
stirring until complete dissolution. 50 mg free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was added to the solution and
the mixture was stirred at room temperature for 24 hours. The
precipitate was collected by vacuum filtration, washed with diethyl
ether, dried under vacuum at 50.degree. C. for 14 hours and
analyzed by XRPD (see FIG. 2B), TGA/EGA and DSC.
Example II.3.1
Preparation of hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0366] In a 100 ml crystallizer, equipped with a magnetic stirring
bar and condenser, 2 g free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was dissolved in acetone under
stirring. At room temperature 438 .mu.l (1 equivalent) of
hydrochloric acid was added drop wise. A slight yellow precipitate
was immediately formed, and the mixture was stirred at room
temperature for 3 hours. The solid was filtered, dried under vacuum
at 40.degree. C. for 24 hours (yield: 81.5%) and analyzed by XRPD
(see FIG. 3A).
Example II.3.2
Preparation of hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0367] 50 mg of free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was dissolved in 3 ml acetone.
At room temperature, 22 .mu.l of 37% hydrochloric acid was added
and the mixture was stirred at room temperature for 24 hours. The
precipitate was recovered under vacuum, washed with diethyl ether,
dried under vacuum at 50.degree. C. for 24 hours, and analyzed by
XRPD (see FIG. 3B), TGA/EGA and DSC.
Example II.4.1
Preparation of fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0368] 15.46 mg of fumaric acid was dissolved in 1 ml methanol
under stirring until complete dissolution. 50 mg free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was added to the solution and
the mixture was stirred at room temperature until complete
dissolution. The solvents were evaporated at room temperature for
48 hours and a yellow oil was obtained. 1 ml acetone was added and
the mixture stirred stirred at room temperature for 2 hours. A
yellow precipitate was recovered under vacuum, washed with diethyl
ether, dried under vacuum at 50.degree. C. for 14 hours, and
analyzed by XRPD (see FIG. 4A), TGA/EGA and DSC.
Example II.4.2
Preparation of fumarate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form
[0369] 30.91 mg of fumaric acid was dissolved in 2 ml methanol
under stirring until complete dissolution. 50 mg free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate was added to the solution and
the mixture was stirred at room temperature until complete
dissolution. The solvents were evaporated at room temperature for 3
days and a yellow oil was obtained. 1 ml acetone was added and the
mixture stirred stirred at room temperature for 2 hours. A yellow
precipitate was recovered under vacuum, washed with diethyl ether,
dried under vacuum at 50.degree. C. for 14 hours, and analyzed by
XRPD (see FIG. 4A), TGA/EGA and DSC.
[0370] The following are further embodiments of the invention:
Embodiment 1
[0371] A free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form; or a salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form, wherein said
salt is the citrate, hydrochloride, fumarate, adipate, maleate or
sebacate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate.
Embodiment 2
[0372] A free form of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form.
Embodiment 3
[0373] The free form according to embodiment 2, wherein the free
form is in crystalline form.
Embodiment 4
[0374] The free form according to embodiment 3, wherein the free
form is characterized by an XRPD pattern substantially the same as
the XRPD pattern shown in FIG. 1A.
Embodiment 5
[0375] The free form according to any one of embodiments 2 to 4,
wherein the free form is in substantially pure form.
Embodiment 6
[0376] The free form according to any one of embodiments 2 to 4,
wherein the free form has a purity greater than 90 weight %.
Embodiment 7
[0377] A salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in solid form, wherein said
salt is the citrate, hydrochloride, fumarate, adipate, maleate or
sebacate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate.
Embodiment 8
[0378] The salt according to embodiment 7, wherein the salt is the
citrate of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
Embodiment 9
[0379] The salt according to embodiment 8, wherein the salt is
characterized by an XRPD pattern substantially the same as the XRPD
pattern shown in FIG. 2A.
Embodiment 10
[0380] The salt according to any one of embodiments 7 to 9, wherein
the salt is in substantially pure form.
Embodiment 11
[0381] The salt according to any one of embodiments 7 to 9, wherein
the salt has a purity greater than 90 weight %.
Embodiment 12
[0382] A pharmaceutical composition, which comprises a free form as
defined in any one of embodiments 2 to 6 as active ingredient and
at least one pharmaceutically acceptable carrier.
Embodiment 13
[0383] A pharmaceutical composition, which comprises a salt as
defined in any one of claims 7 to 11 as active ingredient and at
least one pharmaceutically acceptable carrier.
Embodiment 14
[0384] A method of preparing a citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form comprising
the steps of
(a) preparing a solution of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate and citric acid in acetone,
wherein the
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate: citric acid ratio is about
1:2; (b) adding to the solution of step (a) an ether antisolvent,
e.g. diethyl ether, until an acetone:ether antisolvent volume ratio
from 1:1 to 1:5 is reached; and (e) isolate the solids by
filtration to obtain the citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
Embodiment 15
[0385] A method of preparing a hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form comprising
the steps of
(a) preparing a solution of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in acetone; (b) adding to the
solution of step (a) hydrochloric acid until a
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate:hydrochloric acid ratio of
about 1:1 is reached; and (e) isolate the solids by filtration to
obtain the hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate in crystalline form.
BRIEF DESCRIPTION OF THE DRAWINGS
[0386] FIG. 1A shows the XRPD pattern for Form A of the free form
of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 2500 counts and wherein the first scale mark is 2500
counts.
[0387] FIG. 1B shows the XRPD pattern for Form B of the free form
of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 1000 counts and wherein the first scale mark is 1000
counts.
[0388] FIG. 2A shows the XRPD pattern for Form A of the citrate
salt of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
1.0 2-theta and wherein the first scale mark is 3.0 2-theta. The
y-axis represents Lin (Counts), wherein a scale mark corresponds to
1 count and wherein the first scale mark is 1 count.
[0389] FIG. 2B shows the proton-NMR spectrum for Form A of the
citrate salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate The x-axis represents the
Chemical Shift (ppm), wherein a scale mark corresponds to 0.05 ppm
and wherein the first scale mark is 8.45 ppm. The y-axis represents
Normalized Intensity, wherein a scale mark corresponds to 0.005 and
wherein the first scale mark is -0.02.
[0390] FIG. 2C shows the XRPD pattern for Form B of the citrate
salt of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 250 counts and wherein the first scale mark is 250
counts.
[0391] FIG. 3A shows the XRPD pattern for Form A of the
hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
1.0 2-theta and wherein the first scale mark is 3.0 2-theta. The
y-axis represents Lin (Counts), wherein a scale mark corresponds to
5 counts and wherein the first scale mark is 5 counts.
[0392] FIG. 3B shows the XRPD pattern for Form B of the
hydrochloride salt of
1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 100 counts and wherein the first scale mark is 100
counts.
[0393] FIG. 4A shows the XRPD pattern for Form A of the fumarate
salt of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 1000 counts and wherein the first scale mark is 1000
counts.
[0394] FIG. 4B shows the XRPD pattern for Form B of the fumarate
salt of 1-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)piperidin-4-yl
4-cyclobutylpiperazine-1-carboxylate. The x-axis represents the
angle of refraction 2-theta, wherein a scale mark corresponds to
2.5 2-theta and wherein the first scale mark is 5.0 2-theta. The
y-axis represents Intensity (counts), wherein a scale mark
corresponds to 250 counts and wherein the first scale mark is 250
counts.
* * * * *